WO2000003008A2 - Recombinant haploid or diploid yarrowia lipolytica cells for the functional heterologous expression of cytochrome p450 systems - Google Patents

Recombinant haploid or diploid yarrowia lipolytica cells for the functional heterologous expression of cytochrome p450 systems Download PDF

Info

Publication number
WO2000003008A2
WO2000003008A2 PCT/DE1999/002174 DE9902174W WO0003008A2 WO 2000003008 A2 WO2000003008 A2 WO 2000003008A2 DE 9902174 W DE9902174 W DE 9902174W WO 0003008 A2 WO0003008 A2 WO 0003008A2
Authority
WO
WIPO (PCT)
Prior art keywords
cells
plasmids
lipolytica
expression
cytochrome
Prior art date
Application number
PCT/DE1999/002174
Other languages
German (de)
French (fr)
Other versions
WO2000003008A3 (en
Inventor
Thomas Juretzek
Stephan Mauersberger
Gerold Barth
Original Assignee
Technische Universität Dresden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technische Universität Dresden filed Critical Technische Universität Dresden
Publication of WO2000003008A2 publication Critical patent/WO2000003008A2/en
Publication of WO2000003008A3 publication Critical patent/WO2000003008A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces

Definitions

  • the invention relates to recombinant haploid or diploid Yarrowia (Y.) lipolytica cells for the functional heterologous expression of cytochrome P450 (P450) systems, plasmids for transforming the cells, a method for producing the cells and the use of these for converting substances.
  • Y. recombinant haploid or diploid Yarrowia
  • P450 cytochrome P450
  • Monooxygenases of the cytochrome P450 type are common in organisms on the entire phylogenetic scale. They catalyze NAD (P) H and independent reactions in a variety of anabolic and catabolic pathways.
  • Cytochrome P450 enzymes catalyze the oxidation of numerous physiological substrates such as steroids, fatty acids, eicosanoids and others. Lipid metabolites. Many forms of P450 metabolize xenobiotics such as drugs, alcohol, procarcinogens, antioxidants, organic solvents and anesthetics. The primary sequences of more than 600 different P450 forms are currently known. They are combined into a super gene family (CYP) based on characteristic sequence features (reviews by Nelson et al. 1993 DNA Cell Biol 12: 1-38; Nelson et al. 1996 Pharmacogenetics 6: 1-42).
  • P450 systems are characterized by their high regio- and stereoselectivity and by the oxidation of a wide variety of mostly hydrophobic substrates. P450-catalyzed biotransformation reactions are therefore of particular interest for biotechnological applications.
  • heterologous expression of cytochrome P450 cDNA's or genes in a suitable host is a promising way to use the variety of the catalytic activity of P450 enzymes in biotransformation systems.
  • yeasts are well suited due to their eukaryotic cell structure to functionally actively expand ER-bound P450 forms. Furthermore, due to their relatively simple technological handling and genetic and genetic engineering manipulation, they offer favorable conditions for the creation of biotransformation systems.
  • the yeast cells can also be used as "recombinant cell factories" Yeast Saccharomyces cerevisiae has so far been used mainly for the functional heterologous expression of membrane-bound P450 forms from suckers, plants and eukaryotic microorganisms to high cell concentrations (high cell density fermentation) and used for biotransformation
  • ADH1- Promotors (Oeda et al 1985 DNA 4 203-210) were a large number of different P450 forms (ER-standing and mitochondrial P450 isoforms) in S cerevisiae under the control of various strong promoters (ADH1, CUP1, PH05, GAL7, GAL10, GAL-CYC , PGK et al.) Functionally expanded (reviews by Yabusaki and Oh
  • the yeast S cerevisiae has the disadvantage that the relatively low concentrations and activities of its own microsomal electron transport components (NADPH-P450 reductase, NADH-cytochrome b 5 reductase, cytochrome b 5 ) can become a limiting factor for the catalytic activity of high concentrations of a heterologous P450 Therefore, different strategies and successes were attempted to increase the effectiveness of the microsomal electron transfer to the P450 - by additional expression of the genes of different NADPH-P450 reductases and in selected cases of cytochrome b 5 or by fusion of the reductase and P450 structural genes ( Urban et al 1990 Biochemie 72 463-472, Sanglard et al 1990 Biocatalysis 4 19-28, Sakaki et al 1990 DNA Cell Biol 9 603-614, Yabusaki and Ohkawa 1991 In Frontiers in Biotransformation, Ruckpaul K, Rein H, eds, Vol 4, pp 87-126, Akade
  • Saccharomyces yeasts A particular disadvantage of Saccharomyces yeasts is the relatively low absorption capacity or absorption rate for lipophilic compounds such as fatty acids and alkanes (Kohlwein and Paltauf 1984 Biochim Biophys Acta 792 310-317, Dell'Angeiica et al 1992 Comp Biochem Physiol 102B 261-265, Dell'Angeiica et al 1996 Biochem Mol biol Int 39 439-445)
  • the catalytic performance of heterologous P450 in S cerevisiae is therefore usually low, which is evident from a insufficient substrate and electron transport in this yeast is related.
  • yeast Kluyveromyces lactis functional expression, but with low activity, of P450 scc and of adrenodoxin under the control of the lactase promoter has been reported (Mencke et al. 1990, 19th th FEBS meeting, Budapest August 1990, abstracts).
  • the alkane-utilizing yeasts e.g. Candida maltosa, C. tropicalis or Y. lipolytica
  • Candida maltosa e.g. Candida maltosa, C. tropicalis or Y. lipolytica
  • Y. lipolytica e.g. Candida maltosa, C. tropicalis or Y. lipolytica
  • Well-developed host-vector systems are available for the yeasts Y. lipolytica and C.
  • Candida yeasts are overall not very suitable hosts for the functional heterologous expression (Zimmer and Schunck 1995 Yeast 11: 33-41; Sugiyame et al Yeast 11: 43-52; overview in Mauersberger et al. 1996 Chapter 12.
  • Candida maltosa In: Non-conventional Yeasts in Biotechnology, Wolf K, ed, Springer Verlag, Heidelberg, pp 411 -580). The C.
  • maltosa system is therefore only good for the expression of homologous P450 under the control of the homologous promoters GAL1-GAL10, PGK1 and ALK suitable, but not for the expression of heterologous proteins (Ohkuma et al. 1995 Biochim Biophys Acta 1236: 163-169).
  • the alkane-utilizing yeast Y. lipolytica has been intensively investigated biochemically, genetically and molecular biologically in the past years (reviews in Weber and Barth 1988, CRC Crit Rev Biotechnol 7: 281-337; Gaillardin and Heslot 1988 J Basic Microbiol 28: 161-174; Barth and Gaillardin 1996 Chapter 10 Yarrowia lipolytica In: Wolf K / Ed / Non-conventional Yeasts in Biotechnology, Springer Verlag Berlin, pp 313-388; Barth and Gaillardin 1997 FEMS Microbiol Rev 19: 219-237).
  • Another problem is the fact that natural high-copy plasmids as found in S. cerevisiae are not known in Y. lipolytica and only artificial, autonomously replicating low-copy plasmids exist.
  • the autonomously replicating plasmids of the type plNA237 (LEU2 CEN-ARS18) or plNA443 (URA3 ARS68-CEN) carry / ARS / CE / V sequences and therefore only occur with 1-2 copies per cell. Plasmids carrying only the / ARS sequences can occur with multiple copies per cell.
  • transformants carrying such plasmids are relative unstable and lose these plasmids after a few generation changes (Fournier et al.
  • Plasmids that are integrated into the genome are characterized by high stability even under non-selective cultivation conditions.
  • the known plasmids of this type are generally integrated into the mutated genes Ieu2, Iys5, ura3 or xpr2 [locus: mutated genes LEU2, LYS5, URA3 or XPR2] and complement the corresponding mutation. These plasmids are integrated into the genome as a copy.
  • the vectors suitable as integrative multi-copy plasmids carry the selection marker gene URA3, the promoter function of which is restricted by deletion (URA3d).
  • URA3d the promoter function of which is restricted by deletion
  • the first integrative multi-copy plasmids plNA764 to plNA774 described for Y. lipolytica (Le Dali et al. 1994 Curr Genet 26: 38-44; Barth and Gaillardin 1996 Chapter 10 Yarrowia lipolytica In: Wolf K / Ed / Non-conventional Yeasts in Biotechnology, Springer Verlag Berlin, pp 313-388; Barth and Gaillardin 1997 FEMS Microbiol Rev 19: 219-237) are incorporated into the chromosomal repetitive sequences of the ribosomal DNA (rDNA G unit, Fournier et al. 1986 Gene 42: 273-282) integrated.
  • the URA3d gene whose deleted promoter regions are only 41 to 6 base pairs "upstream" from the start codon ATG, serves as the selection marker gene.
  • the average stable copy number is between 5 (plNA767) and 13 (plNA772) copies per cell. With plasmid plNA773, originally 20-60 copies per cell could be integrated.
  • a decisive disadvantage of these plasmids is that no stable copy numbers could be obtained under inducing and non-selective expression conditions or the integrated plasmid copies were lost.
  • a further disadvantage of these plasmids is the use of the plasmid pBR322 as a base vector for the amplification in E. coli, which requires a low number of plasmids, which can only be increased by adding chloramphenicol. This makes the extraction of the plasmids more complex and lengthy.
  • the plasmids plNA1066 and plNA1067 are suitable for the expression of homologous and heterologous proteins under the control of the XP 2 promoter.
  • these plasmids also have the same disadvantages as the vectors pNA776 to pNA773. Furthermore, they have no "multiple cloning site".
  • the expression cassette can be completed using the interfaces Srfl, Apa ⁇ and BglU. An exchange of expression cassettes for the expression of proteins under the control of other promoters is only possible in several cloning steps. It is therefore of great interest to develop plasmids which allow an exchange of DNA modules (expression cassettes, gene banks, etc.) and are suitable for multiple integration into the genome.
  • the task now is to provide a new, easy-to-use system for the heterologous functional expression of cytochrome P450 genes in the yarrow Yarrowia lipolytica.
  • the object is achieved by recombinant haploid or diploid Y. lipolytica cells with the features mentioned in claim 1.
  • Advantageous configurations of the cells result from the dependent subclaims 2 to 11.
  • the invention is further solved by plasmids for the production of recombinant haploid or diploid Y. lipolytica cells with the features mentioned in claim 12.
  • Advantageous designs of the plasmids result from the dependent subclaims 13 to 19.
  • the invention is also achieved by a method for producing recombinant haploid or diploid Y. lipolytica cells with the features mentioned in claim 20.
  • Advantageous variants of the method result from the dependent subclaims 21 to 23.
  • Uses of the recombinant haploid or diploid Y. lipolytica cells are described in claims 24 and 25.
  • new low-copy and high-copy plasmids suitable for autonomous replication or for the multiple integration of expression cassettes which are under the control of an adjustable promoter (for example the ICL1 gene, coding for the isocitrate lyase) of the yeast Y. lipolytica recombinant haploid or diploid Y. lipolytica cells are produced.
  • an adjustable promoter for example the ICL1 gene, coding for the isocitrate lyase
  • yeast Y. lipolytica recombinant haploid or diploid Y. lipolytica cells are produced. It was surprisingly found that these plasmids integrate with a high copy number into the genome and can be obtained in Yarrowia // o / yf / ca transformants regardless of the integration sites and cultivation conditions.
  • the cells obtained in this way are suitable for the microbial oxidation of hydrophobic compounds and, by simple cultivation of the recombinant yeasts, lead to good yields of the oxidation product, in particular steroids and other hydrophobic compounds.
  • the yeast V. lipolytica is changed by transformation with new expression vectors (plasmids carrying expression cassettes) into the genome in such a way that Y. lipolytica cells are able, by simple culture control on media with a suitable carbon source, for the functional expression of heterologous proteins, in particular cytochrome P450 Enzymes to get.
  • heterologous proteins in particular cytochrome P450 Enzymes to get.
  • the plasmids also provide vectors which are easy to handle and which can be stably integrated into the genome of the yeast Y. lipolytica in high copy numbers and thereby allow the concentration of the protein to be expressed heterologously to be increased.
  • a particular advantage of these plasmids is that The presence of a "multiple cloning site", so that different types of DNA modules (expression cassettes) can be inserted into the vectors quickly and easily.
  • the plasmids can be integrated into the repetitive sequences of Y. lipolytica (LTR element ZETA, rDNA cluster). The task is solved in an advantageous manner by constructing suitable plasmids for multiple integration into the genome of Y. lipolytica and thereby increasing the number of copies of expression cassettes with controllable strong promoters (for example ICL1 promoter).
  • the expression cassettes for the heterologous expression of proteins in Y. lipolytica consisting of the functionally active promoter and terminator (for example from ICL1) and the heterologous genes to be expressed, are converted into autonomously replicating low-copy plasmids or integrative high-copy plasmids the yeast is transformed and expressed.
  • the object is advantageously achieved by monooxygenase systems which consist of cytochrome P450 and corresponding NADPH-cytochrome P450 reductase, which are simultaneously expressed in Y. lipolytica.
  • monooxygenase systems consist of cytochrome P450 and corresponding NADPH-cytochrome P450 reductase, which are simultaneously expressed in Y. lipolytica.
  • a homologous or heterologous NADPH cytochrome P450 reductase can also be co-expressed with the P450 under the control of a suitable promoter.
  • the hydrophobic compounds are brought into the culture solution from such genetically modified Y. lipolytica cells, as a result of which the expressed enzymes bring about selective hydroxylation. After the reaction, the hydroxylation products are separated off.
  • the transformants of the yeast Y. lipolytica used for the invention can be cultivated on long- and medium-chain n-alkanes or ethanol for the induction of the expression of the heterologous genes.
  • Preferred enzyme systems are steroid hydroxylating cytochrome P450 forms, a NADPH cytochrome P450 reductase from Y. lipolytica or other origin.
  • the recombinant yeast cells cultured on n-alkane in particular show the highest specific conversion rates (per cell or per molecule of P450 enzyme) for the substrate progesterone in 17 ⁇ -hydroxy-progesterone in comparison with cells cultivated on ethanol.
  • the hydrophobic substrates in particular steroid compounds, are treated in cultures of intact cells (cell suspensions).
  • the substances to be hydroxylated are finely ground to the cell cultures or added dissolved in organic solvents, for example hexadecane or ethanol. The process is carried out at low temperatures between 28-32 ° C.
  • the conversion of at least 0.22 g substrate / L cell culture is usually largely completed after 10 to 30 hours of culture.
  • the reaction is terminated by direct extraction of the culture fluid with isobutyl methyl ketone (MiBK) or dichloromethane (DCM) or after acidification with dilute sulfuric acid.
  • the conversion can be checked by means of chromatography during the cultivation period.
  • Contents of the invention are recombinant Yarrowia lipolytica transformants and the new vectors pBD64, p64zb, pBD67 and p67zb or their derivatives with a promoter p64ICLpro and p67ICLpro or functional expression cassettes (for example p64IL43, p67IL43, p64IC17 ⁇ or p67IC17 ⁇ ) into the gene of multiple integration Y. lipolytica are suitable.
  • the structure of these vectors is shown in Fig. 3-7.
  • the production of the recombinant Yarrowia // po / yfrca transformants is advantageously solved by the construction of a series of new vectors based on an E. co // vector with a multiple cloning site, which contains a marker gene for the selection of multi-copy transformants and others contain chromosomal DNA segments from Y. lipolytica, which are used for multiple integration into the genome of the yeast Y. lipolytica.
  • vectors carry the ampicillin resistance gene (amp R ) as selection markers for the amplification of the plasmid DNA in E. coli and can be easily prepared from E. coli in high yields due to their high copy number.
  • the sequences for integration into the genome of the yeast Y. lipolytica (rDNA, ZETA) and the selection marker gene URA3d4 are obtained by cloning from the plasmids plNA1064 and plNA1067 (Fig. 2). DNA modules, for example expression cassettes, can be cloned into the "multiple cloning site" well.
  • the resulting basic plasmids pBD64 (rDNA) and pBD67 (LTR ZETA, Figs. 3 and 4) according to the invention can be easily obtained in an advantageous embodiment of the invention in a few steps
  • Expression cassettes preconstructed into the "multiple cloning site" consisting of a strong and easily regulated homologous promoter (eg ICL 7 promoter), a heterologous gene (eg lacZ or CYP17) and a homologous terminator (eg ICL1 terminator), easy to insert
  • a strong and easily regulated homologous promoter eg ICL 7 promoter
  • a heterologous gene eg lacZ or CYP17
  • a homologous terminator eg ICL1 terminator
  • these new plasmids are then used for the multiple integration of the expression cassettes into the genome (chromosomal sequences of the rDNA or LTR ZETA) from V lipolytica.
  • the transformants produced in this way have a stable copy number of the expression cassettes (from about 10-14)
  • they show a significantly higher expression of heterologous proteins compared to autonomously replicating plasmids (copy number 1-2), as is the case for the reporter protein ß-galactosidase (lacZ gene from E coli, Fig. 11) and the cytochrome P45017 ⁇ (CYP17 gene of the Beef, Fig. 13-14) can be shown
  • a special feature important for the implementation of the invention is that the transformants obtained can be crossed with other Y lipolytica strains with a high copy number of the expression cassettes. This enables advantageous natural traits to be crossed or the expression cassettes of at least two heterologous genes to be co-expressed in one host
  • diploid strains obtained in this way are also distinguished by the stability of the expression cassettes and, surprisingly, are particularly well suited to the P450-catalyzed biotransformation during growth on n-alkane and ethanol
  • the method according to the invention with recombinant Y lipolytica cells is distinguished by high hydroxylation rates.
  • the steroid progesterone is characterized by Y. lipolytica better than with the previously investigated recombinant cells of S. cerevisiae, which also express a steroid hydroxylating P45017 ⁇ .
  • Yarrowia lipolytica strains B204-12A-213 (MATB Ieu2 ura3 leaky) PO1 d (MATA leu2-270 ura3-302 xpr2-322 SUC2)
  • T4 PO1 d p67IC17 ⁇ T4
  • T4 for short integrative transformants T4 of the strain PO1d with the plasmid p67IC17 ⁇ (URA3d4 ZETA) linearized in the ZETA element, which is approx. 8-10 Copies of the expression cassette
  • A1-5 (MATB with Alk + ) natural isolate.
  • A15T4 Alk + , prototrophic) - diploid strain, created by crossing the two parent strains A1-5 (MATB met ' Alk * ) PO1 d (p67IC17 ⁇ T4) Saccharomyces cerevisiae: GRF18 (MAT ⁇ his3-11 his3-15 leu2-3 Ieu2-112 can R )
  • YEp51 (Broach JR, Li YY, Wu L-CC, Jayaram M, 1983, Vectors for high-level inducible expression of cloned genes in yeast. In: Experimental Manipulation of Gene Expression [Inoye M, ed], Academic Press New York, 83-117) contains the LEU2 gene of this yeast as a selection marker, the GAL1-GAL 7O promoter and sequences from the 2 ⁇ plasmid of S cerevisiae as a termination area and for ensuring high levels (50-100) copy numbers of these ARS plasmids YEp5117 ⁇ (high-copy plasmid, see Fig.
  • the copy number of this vector in Y lipolytica is 1 -3 per cell (Fournier et al 1993 Proc Natl Acad Sei USA 90 4912-4916)
  • plNA1064 and plNA1067 are based on the E co // vector pBR322 and carry the multi-copy selection marker gene URA3d4.
  • the l / P43 promoter consists of 8
  • the plNA1064 carries the rDNA sequence for the integrative transformation into the host's rDNA sequence (G unit) (Fournier et al 1986 Gene 42 273-282).
  • the plNA1067 carries the sequence of the LTR ZETA (long terminal repeat) of the retrotransposon Ylt1 from Y lipolytica (Le Dali et al 1995 abstract "First Yarrowia lipolytica International Meeting” Pans-G ⁇ gnon)
  • the cDNA for the CYP17 was obtained from the plasmid pCMV17 ⁇ (J Biol Chem 266 5898-5904, 1991) and encoded for the cytochrome P45017 ⁇ of the adrenal gland Beef. This plasmid was kindly provided by Prof. M. Waterman (Vanderbilt University Nashville).
  • M Minimal medium (M) for the cultivation of Y. lipolytica in the fermenter (Scheller U et al. 1996 Methods Enzymol 272: 65-75).
  • the E co // vector pUCBM21 was completely digested with the restriction endonuclease ⁇ / del.
  • the single-stranded ends of the digested DNA were treated with polymerase I (Klenow fragment) padded.
  • the DNA was cleaved with ßamHI.
  • the vector prepared in this way was ligated in each case with the EcoRI / ⁇ amHI fragments from the vectors plNA1064 (3178 bp) and plNA1067 (2423 bp).
  • the vectors pNA1064 and 1067 (Fig. 2) were digested with EcoRI and the single-stranded ends were filled in with the Klenow fragment.
  • the DNA was then digested with ßamHI.
  • the resulting vectors are the plasmids pBD64 (with rDNA as the target sequence) and pBD67 (with ZETA element as the target sequence) (FIG. 3). These plasmids were now suitable for incorporating DNA fragments (eg expression cassettes) into the "multiple cloning site”.
  • the plasmids p64ICLpro and p67ICLpro (carry ICL 7 promoter)
  • the plasmids pBD64, pBD67 and pYLI131 D (Juretzek et al. 1997 DE 195 25 282 A1) were digested with the residual endonucleases ßamHI and Kpnl.
  • the 2162 bp ßamHI / pni fragment containing the ICL1 promoter was ligated with the pnl / ßamHI opened plasmids pBD64 and pBD67.
  • the resulting vectors were p64ICLpro and p67ICLpro.
  • These plasmids contain the ICL1 promoter (Fig. 5).
  • the plasmids p64ICLpro and p67ICLpro were digested with ßamHI and then dephosphorylated.
  • the 3833 bp ⁇ amHI fragment was isolated from the plasmid plL43 (Juretzek et al. 1995 DE 195 25 282 A1) and ligated to the opened vectors.
  • the resulting plasmids were p64IL43 and p67IL43 (Fig. 6) and contain the expression cassette / C - / - promoter // acZ gene // C • / terminator.
  • cytochrome P45017 ⁇ from the bovine adrenal cortex
  • the cloning of the expression cassette for the heterologous expression of CYP17 (bovine) under the control of the ICL 1 promoter was carried out in several partial steps, by recloning the CYP17 cDNA into the vector pYLI131 D and by amplifying DNA which indicated the correct fusion of the CYP17 ORF enables the ICL 7 promoter.
  • the part of the CYP17 cDNA coding for the C-terminus was extracted from the vector YEp5117 ⁇ (Fig.
  • Amplification ICL 7 promoter / intron fragment Primer 1, 5'-TAGATCTGGGGATCCCCAGTAGACTGACCAAGC-3 '; Primer 2, 5'-CACTGGGTTAGTACGGG-3 '.
  • Amplification of the CYP17 fragment :
  • the fragments were recombined at overlapping sequences and amplified with primers 1 and 4.
  • the recombined PCR product was inserted into the preliminary construct as a ⁇ gr / II fragment and the autonomously replicating low-copy vector plC17 ⁇ (FIG. 9) was obtained.
  • the vectors p64IC17 ⁇ and p67IC17 ⁇ were obtained by cloning as an ul / pnl fragment into the vectors p64IL43 or p67IL43 (FIG. 6).
  • the vectors pBD64 and pBD67 were partially hydrolyzed with the restriction endonuclease Hind ⁇ , the free DNA ends were filled in with the enzyme Klenow fragment and religated.
  • the plasmids with a / - // ndlll site in the multiple cloning site were isolated and hydrolyzed again with H / ndlll.
  • the linearized fragments were dephosphorylated and ligated with H / ' ll digested PCR fragments described below.
  • the corrective vectors p64zb and p67zb were isolated.
  • the PCR fragment for insertion into the vector pBD64 was amplified from the same plasmid with the oligonucleotides 5'-attaagcttcggtatgataggaagag-3 'and 5'-tggaagcttgggagaccccaagg-3'.
  • the oligonucleotides 5'-tgtaagcttcgtacgggagagttagtcatccgac-3 'and 5'-aagaagcttaagggaggtgtcctgtccac-3' the plasmid pBD67 was used to synthesize the PCR fragment for insertion into the vector pBD67.
  • the third ⁇ / of1 site (plasmid p67zb) or Sacll site (plasmid p64zb) must be eliminated by inserting expression cassettes into the multiple cloning site since hydrolysis with the respective enzymes involves the separation of the E. co // - containing DNA is done.
  • the total DNA of the investigated transformants was isolated and completely digested with ßamHI.
  • the DNA obtained in this way was separated by gel electrophoresis in 0.8% agarose and blotted on a nylon membrane.
  • 32 P-radioactively labeled DNA of the known ICL 7 intron from Y. lipolytica was used as the probe.
  • the distribution of the radioactivity and its intensity was analyzed by means of the phosphorimager "Storm" (MD).
  • the copy number was determined from the ratio of the intensity of the 3833 bp band (integrated / acZ expression cassette) and the 2281 bp band (chromosomal homologous ICL1 gene).
  • the number of copies found was between 4 and 38 copies per cell (Fig. 10).
  • the average number of copies is 10 to 14 copies per cell.
  • Transformants with lower number of copies grew more slowly than the wild type.
  • Transformants with average or higher number of copies grew comparatively quickly to the wild type.
  • Embodiment 9 Expression of the ⁇ -galactosidase activity of multi-copy transformants
  • the transformants were pre-cultivated on selection medium with glucose for 28 h at 28 ° C. and after washing twice with medium without a C source on selection medium with ethanol to form the ⁇ -galactosidase implemented.
  • the optical density (OD 6 oo) at the start of the induction was 0.7-1.
  • samples were taken every 30 minutes for 13 hours (Reynolds and Lundblad 1994 In: Current Protocols in Molecular Biology, Ausubel et al. / Eds / J Wiley, New York, Vol 2, Unit 13.6. 1 ).
  • the expression of the ⁇ -galactosidase was determined using the low-copy expression system plL43 (Juretzek et al. 1995 D195 25 282 A1) in the strain PO1 d (Fig. 11).
  • transformants were cultivated in non-selective full medium (YPD), in minimal medium YNB with uracil and glucose and in minimal medium with uracil and ethanol over 20 generations. The number of copies was determined as in point 5. After 20 generations, the tested transformants carried as many copies as the original transformants. Transformants with 10 to 14 copies per cell grow normally and the copy numbers are stable in the cell population.
  • the cells in the shake flask were in Minimal medium (M) cultivated with inducing and non-inducing C sources. At the time of starting the main culture and every 3 h for 25 h, samples were taken and the OD 6 oo was adjusted to an OD 6 oo of 2 to 4 by adding the appropriate medium. 100 nmol of 3 H-progesterone (dissolved in ethanol) were added to 1 ml of this dilution and the cultures were cultured in a shaking incubator at 28 ° C. and 240 rpm for 30 min and 60 min, respectively.
  • M Minimal medium
  • 3 H-progesterone dissolved in ethanol
  • the diploid strain A15T4 was generated by crossing the strains A1-5 and T4 (diploidization according to Barth and Gaillardin 1996) The dimorphic fungus Yarrowia lipolytica. in: Nonconventional Yeasts in Biotechnology, Wolf K, ed, Springer Verlag, Heidelberg, pp 313-388). This strain was used to convert progesterone to 17 ⁇ -hydroxprogesterone in a 1 liter bioreactor (Fig. 15).
  • M Minimal medium (M) for the cultivation of Y. lipolytica in the fermenter (Scheller U et al. Methods in Enzymology 272: 65-75 1996).
  • Variant A 1) 900 ml M (0.2% glucose) - Start with 100 ml 2nd preculture Start-ODeoo approx. 1 -1.5
  • Fig. 1 Detection of the repetitive sequences rDNA and ZETA in different Y. // po / yf / ca strains by Southern hybridization.
  • chromosomal DNA 0.5 ⁇ g was digested with the restriction enzyme EcoRI and separated by gel electrophoresis.
  • the ZETA sequence (A) from the plasmid p67ICLpro or rDNA (G-Unit) sequence (B) from the plasmid p64ICLpro were used as fluorescein-labeled probes.
  • Fig. 2 Restriction maps of the starting plasmids for the construction of new vectors for multi-copy integration into the genome of Y. lipolytica.
  • the plasmid plNA1067 contains the URA3d4 gene, which is greatly shortened in the promoter region, as a selection marker for the multi-copy integration, the sequence of the ZETA element of the LTR (long terminal repeat) from the retrotransposon Ylt1 from Y. lipolytica as the destination for the integration and the promoter and Terminator of the XPR2 gene, the alkaline protease from Y lipolytica.
  • the plasmid plNA1064 contains a fragment from the rDNA gene (G unit) from Y. lipolytica for integration into the genome. Both plasmids were developed by Dr. J.-M. Nicaud (INRA-CNRS, Thiveral-Grignon, France) received.
  • Fig. 3 Restriction maps of the newly constructed basic plasmids pBD67 and pBD64 for multi-copy integration into the genome of Y. lipolytica.
  • the plasmids are based on the E coli vector pUCBM21. They carry the URA3d4 gene, which is defective in the promoter, as a multi-copy selection marker.
  • the plasmid pBD64 is suitable for integration into the rDNA (G unit), the plasmid pBD67 can be used for integration into the LTR element ZETA (long terminal repeat) of the retrotransposon Ylt1.
  • rDNA rDNA fragment from Y. lipolytica G unit
  • URA3d4 defective URA3 gene from Y. lipolytica
  • amp R ampicillin resistance gene
  • ZETA LTR (long terminal repeat) of the retrotransposon Ylt1.
  • Vector is based on the plasmid pBD67 (Fig. 3) and additionally carries a shortened ZETA element. After digestion with the residual endonuclease ⁇ / of1, the DNA originating from the bacterium E coli can be separated.
  • URA3d4 selection marker
  • ZETA LTR of the retrotransposon Ylt1 from Yarrowia lipolytica
  • ZETA ' part of the LTR of the retrotransposon Ylt1 from Yarrowia lipolytica amp R - ampicillin resistance gene
  • Fig. 5 Restriction maps of the multi-copy vectors p64ICLpro and p67ICLpro.
  • the plasmid p64ICLpro contains the rDNA fragment and the ⁇ JRA3d4 gene from plNA1064 and the ICL - / - promoter.
  • the Sac // site in the rDNA can be used to linearize the plasmid for an integrative transformation into the rDNA cluster (G unit).
  • the plasmid p67ICLpro contains the ZETA element and the URA3d4 gene from the plasmid plNA1067 and the / CL 7 promoter.
  • the NotI site can be used to open the plasmid for subsequent integration into the ZETA elements of the LTR (long terminal repeat of the retrotransposon Ylt1) of the host genome.
  • Heterologous genes (lacZ or CYP17) can easily be inserted into these plasmids after fusion with the ICL1 terminator. This creates complete expression cassettes in the derived plasmids (see Fig. 5 and Fig. 6, explanations of the abbreviations see also Fig 3)
  • Fig. 6 Restriction maps of the multi-copy vectors p64IL43 and p67IL43 for the heterologous expression of the lacZ gene from E. coli in the yeast Y. lipolytica.
  • the vectors are based on the plasmids pBD64 and pBD67 (see FIG. 3) and carry the expression cassette for the lacZ gene under the control of the ICL1 promoter and terminator.
  • RDNA rDNA fragment from Y lipolytica G unit
  • URA3d4 defective URA3 gene
  • amp R ampicillin resistance gene
  • ICLpro / C ⁇ promoter
  • ICLI ICL1- ⁇ ntron
  • ICLt / C / _ 7 " terminator
  • ZETA LTR ZETA (long terminal repeat) of the retrotransposon Ylt1 from Y lipolytica Fig.
  • the vectors are based on the plasmids pBD64 and pBD67 (see FIG. 3) and carry the expression cassette for the CYP17 P450 gene under the control of the ICL1 promoter and terminator. Explanations of the abbreviations see Fig. 6.
  • Fig. 8 Transformation efficiency of competent cells from the strains PO1d and E129 cells were transformed with 200 ng linearized plasmid DNA and 5.0 ⁇ g carrier DNA. The transformants were observed after 3-14 days.
  • Fig. 9 Restriction maps of the autonomously replicating plasmids YEp5117 ⁇ and plC17 ⁇ for the heterologous expression of the cytochrome P45017 ⁇ of the adrenal gland of the bovine in the yeast Yarrowia lipolytica and in the yeast Saccharomyces cerevisiae.
  • the vector YEp5117 ⁇ was developed by Dr. W.-H. Schunck (MDC Berlin-Buch) provided.
  • the cDNA for the CYP17 from the plasmid pCMV17 ⁇ was cloned in several steps into the high-copy yeast shuttle vector YEp51 (LEU2, 2 ⁇ ARS, copy numbers from 50-100).
  • the vector YEp5117 ⁇ allows galactose-inducible expression of P45017 ⁇ in the yeast S. cerevisiae under the control of the GAL10 promoter.
  • the cDNA for the CYP17 was obtained from the plasmid pCMV17 ⁇ (J Biol Chem 266: 5898-5904, 1991) and codes for the cytochrome P45017 ⁇ of the bovine adrenal gland. This plasmid was kindly provided by Prof. M. Waterman (Vanderbilt University Milwaukee).
  • the plasmid plC17 ⁇ is based on the autonomously replicating Iow copy vector plNA237 (ARS18 / CEN, ensures 1-3 copies per cell) for Y. lipolytica and contains an expression cassette for the cytochrome P45017 ⁇ (CYP17) under the control of the ICL1 promoter (ICLp / ICLi / CYP77 / ICLt).
  • the cDNA CYP17 coding for the cytochrome P45017 ⁇ of the bovine, was used in several steps in the Iow-copy vector pYLI131 D for Y. lipolytica instead of the ICL1 structural gene.
  • the cDNA was recombinant PCR directly at the T 3 6oG 3 6i of the 3 'end of the Introns fused in the ICL - / - promoter.
  • the resulting plasmid plC17 ⁇ allows expression of the P45017 ⁇ under the control of the regulated ICL1 promoter after correct splicing of the intron and reforming of the translation start
  • Fig. 10 Copy numbers of the expression cassettes for the lacZ gene under the control of the ICL1 promoter in integrative multi-copy transformants of the Y. lipolytica strain PO1d with the plasmid p64IL43.
  • Selected transformants with the integrative plasmid p64IL43 were cultivated in YNB / glucose medium.
  • the copy number was determined by Southern blot hybridization with the 32 P-labeled ICL 7 intron as a probe.
  • the copy number was calculated from the ratio of the band intensity at 3.8 kb (lacZ cassette) and 2.2 kb (ICL1 as one copy per genome).
  • a transformant with the autonomously replicating ARS / CEN plasmid plL43 served as a comparison.
  • Fig. 11 Dependence of the maximum specific ß-galactosidase activity on the copy number of the expression cassettes in transformants from Yarrowia lipolytica PO1d, which were transformed by the Iow-copy replicative plasmid plL43 or by the multi-copy integrative plasmid p64IL43.
  • a comparison of the maximum specific ß-galactosidase activities after 10 to 12 h of cultivation in minimal medium with 1% ethanol as an inducing C source is shown.
  • the ⁇ -galactosidase activity was determined as Miller units.
  • the copy number of the expression cassette was determined in each transformant with cells from the glucose preculture (cf. FIG. 10).
  • Fig. 12 Evidence of the functional expression of cytochrome P45017 ⁇ of the adrenal gland in a transformant of the yeast Yarrowia lipolytica with the Iow-copy ARS / CEN plasmid plC17 ⁇ under the control of the ICL "/ promoter.
  • Fig. 13 Comparison of the expression systems for cytochrome P45017 ⁇ in the yeast Yarrowia lipolytica (Iow-copy plasmid plC17 ⁇ and Saccharomyces cerevisiae (multi-copy plasmid YEp5117 ⁇ ) when using autonomously replicating plasmids.
  • Fig. 14 Comparison of the specific content of cytochrome P45017 ⁇ after heterologous expression in the yeasts Yarrowia lipolytica and Saccharomyces cerevisiae of plasmids with a high copy number.
  • Fig. 15 Cultivation of the diploid Yarrowia lipolytica strain A15T4 on hexadecane (C16) and biotransformation of progesterone in 17 ⁇ -hydroxy-progesterone. Pre-culture on 1% glucose, culture in 1 L bioreactor on 1% C16. After 14 h of cultivation, add 0.5 g of progesterone in 10 ml of dimethylformamide (DMF) and add 2% of C16.
  • DMF dimethylformamide

Abstract

The invention relates to recombinant haploid or diploid Yarrowia (Y. lipolytica) cells for the functional heterologous expression of cytochrome P450 (P450) systems, plasmids for the transformation of said cells, a method for producing said cells and to the use of same for the transformation of substances. The cells contain plasmids with expression cassettes which consist of promoters and terminators which are functionally active in Y. lipolytica, and genes or cDNA for expressing oligopeptides or proteins and therefore develop properties which are used for substance transformation.

Description

Rekombinante haploide oder diploide Yarrowia lipolytica Zellen zur funktionellen heterologen Expression von Cytochrom P450 SystemenRecombinant haploid or diploid Yarrowia lipolytica cells for the functional heterologous expression of cytochrome P450 systems
Beschreibungdescription
Die Erfindung betrifft rekombinante haploide oder diploide Yarrowia (Y.) lipolytica Zellen zur funktionellen heterologen Expression von Cytochrom P450 (P450) Systemen, Plasmide zur Transformation der Zellen, ein Verfahren zur Herstellung der Zellen sowie die Verwendung dieser zur Stoffumwandlung.The invention relates to recombinant haploid or diploid Yarrowia (Y.) lipolytica cells for the functional heterologous expression of cytochrome P450 (P450) systems, plasmids for transforming the cells, a method for producing the cells and the use of these for converting substances.
Monooxygenasen vom Cytochrom P450 Typ sind in Organismen der gesamten phylogenetischen Skala verbreitet. Sie katalysieren NAD(P)H- und unabhängige Reaktionen in einer Vielzahl von anabolen und katabolen Stoffwechselwegen. Cytochrom P450 Enzyme katalysieren die Oxidation zahlreicher physiologischer Substrate wie Steroide, Fettsäuren, Eicosanoide u.a. Lipidmetabolite. Viele P450 Formen metabolisieren Xenobiotica wie Arzneimittel, Alkohol, Procarcinogene, Antioxidantien, organische Lösungsmittel und Anästhetika. Gegenwärtig sind die Primärsequenzen von mehr als 600 verschiedenen P450 Formen bekannt. Sie werden aufgrund charakteristischer Sequenzmerkmale zu einer Super-Genfamilie (CYP) zusammengefaßt (Übersichten bei Nelson et al. 1993 DNA Cell Biol 12:1-38; Nelson et al. 1996 Pharmacogenetics 6:1-42).Monooxygenases of the cytochrome P450 type are common in organisms on the entire phylogenetic scale. They catalyze NAD (P) H and independent reactions in a variety of anabolic and catabolic pathways. Cytochrome P450 enzymes catalyze the oxidation of numerous physiological substrates such as steroids, fatty acids, eicosanoids and others. Lipid metabolites. Many forms of P450 metabolize xenobiotics such as drugs, alcohol, procarcinogens, antioxidants, organic solvents and anesthetics. The primary sequences of more than 600 different P450 forms are currently known. They are combined into a super gene family (CYP) based on characteristic sequence features (reviews by Nelson et al. 1993 DNA Cell Biol 12: 1-38; Nelson et al. 1996 Pharmacogenetics 6: 1-42).
P450 Systeme zeichnen sich durch ihre hohe Regio- und Stereoselektivität und durch die Oxidation einer großen Vielfalt von meist hydrophoben Substraten aus. P450 katalysierte Biotransformationsreaktionen sind deshalb von besonderem Interesse für eine biotechnologische Anwendung.P450 systems are characterized by their high regio- and stereoselectivity and by the oxidation of a wide variety of mostly hydrophobic substrates. P450-catalyzed biotransformation reactions are therefore of particular interest for biotechnological applications.
Die heterologe Expression von Cytochrom P450 cDNA's oder Genen in einem geeigneten Wirt ist ein vielversprechender Weg zur Nutzung der Vielfalt der katalytischen Aktivität von P450 Enzymen in Biotransformationssystemen.The heterologous expression of cytochrome P450 cDNA's or genes in a suitable host is a promising way to use the variety of the catalytic activity of P450 enzymes in biotransformation systems.
Die heterologe Expression ist oft auch der einzige gangbare Weg zur Charakterisierung individueller P450 Formen, bedingt durch die gleichzeitige Anwesenheit meist mehrerer P450 Isoenzyme mit unterschiedlichen Substratspezifitaten in tierischen und pflanzlichen Geweben und MikroorganismenHeterologous expression is often the only viable way to characterize individual P450 forms due to the simultaneous Presence of usually several P450 isoenzymes with different substrate specificities in animal and vegetable tissues and microorganisms
Die heterologe Expression von membrangebundenen P450 Formen ist heute sowohl in Bakterien (E coli), in Hefen (meist Saccharomyces cerevisiae) als auch in Saugerzellkulturen bzw Insektenzellkulturen möglich (Übersichten bei Yabusaki und Ohkawa 1991 , In Frontiers in Biotransformation, Ruckpaul K Rein H, eds, Vol 4, pp 87-126, Akademie Verlag, Berlin, Guengeπch et al 1991 Methods Enzymol 206 130 Gonzalez und Korzekwa 1995 Annu Rev Pharmacol Toxicol 1995,35 369-390)The heterologous expression of membrane-bound P450 forms is now possible both in bacteria (E coli), in yeasts (mostly Saccharomyces cerevisiae) and in sucker cell cultures or insect cell cultures (reviews by Yabusaki and Ohkawa 1991, In Frontiers in Biotransformation, Ruckpaul K Rein H, eds , Vol 4, pp 87-126, Akademie Verlag, Berlin, Guengeπch et al 1991 Methods Enzymol 206 130 Gonzalez and Korzekwa 1995 Annu Rev Pharmacol Toxicol 1995,35 369-390)
Die Expression in Zellkulturen wird heute gut beherrscht, ist jedoch für eine biotechnologische Nutzung durch meist geringe Expressionsraten und hohen Aufwand für die Kulturfuhrung weniger gut geeignetExpression in cell cultures is well mastered today, but is less suitable for biotechnological use due to mostly low expression rates and high expenditure on culture management
Im Gegensatz zu den sehr guten Ergebnissen mit loslichen bakteriellen P450 Formen (P450CAM, P 50BM3) erfordert die Expression membranstandiger P450 Enzyme in Bakterien (E coli) einen hohen Aufwand relativ komplizierter gentechnischer Modifikationen am P450 Gen selbst (Barnes HJ, Arlotto MP, Waterman MR 1991 Proc Natl Acad Sei USA 88 5597-5601 ) Für die funktionelle Expression in E coli ist außerdem die zusätzliche Bereitstellung von ebenfalls membranstandigen Elektronentransferkomponenten erforderlichIn contrast to the very good results with soluble bacterial P450 forms (P450 CAM , P 50 B M3), the expression of membrane-bound P450 enzymes in bacteria (E coli) requires a great deal of effort to make relatively complex genetic modifications to the P450 gene itself (Barnes HJ, Arlotto MP , Waterman MR 1991 Proc Natl Acad Sei USA 88 5597-5601) For functional expression in E coli, the additional provision of electron transfer components which are also membrane-bound is also required
Dagegen sind Hefen aufgrund ihrer eukaryotischen Zellstruktur gut geeignet, ER- gebundene P450 Formen funktionell aktiv zu expπmieren Sie bieten darüber hinaus aufgrund ihrer relativ einfachen technologischen Handhabbarkeit sowie genetischen und gentechnischen Manipuherbarkeit gunstige Voraussetzungen für die Schaffung von Biotransformationssystemen Die Hefezellen können dazu als "rekombinante Zellfabriken" zu hohen Zeilkonzentrationen (Hochzelldichtefermentation) heranwachsen und zur Biotransformation eingesetzt werden Für die funktionelle heterologe Expression membrangebundener P450 Formen aus Saugern, Pflanzen und eukaryotischen Mikroorganismen wird bislang hauptsächlich die Hefe Saccharomyces cerevisiae genutzt Nach ersten erfolgreichen Versuchen zur Expression einer cDNA von P450c der Rattenleber unter Kontrolle des ADH1- Promotors (Oeda et al 1985 DNA 4 203-210) wurden eine große Anzahl unterschiedlicher P450 Formen (ER-standige sowie mitochondπale P450 Isoformen) in S cerevisiae unter Kontrolle verschiedener starker Promotoren (ADH1, CUP1, PH05, GAL7, GAL10, GAL-CYC, PGK u a ) funktionell expπmiert (Übersichten dazu Yabusaki und Ohkawa 1991 In Frontiers in Biotransformation, Ruckpaul K, Rein H, eds, Vol 4, pp 87-126, Akademie Verlag, Berlin, Urban et al 1990 Biochemie 72 463- 472, Guengench et al 1991 Methods Enzymol 206 130, Schunck et al 1991 Eur J Cell Biol 55 336-345, Renaud et al 1993 Toxicology 22 39-52, Gonzalez und Korzekwa 1995 Annu Rev Pharmacol Toxicol 1995,35 369-390, Dumas et al 1996 Eur J Biochem 238 495-504, Pompon et al 1996 Methods Enzymol 272 51 -64, Pompon et al 1997 J Hepatol 26S2 81-85, Duport et al 1998 Nat Biotechnol 16 186-189)In contrast, yeasts are well suited due to their eukaryotic cell structure to functionally actively expand ER-bound P450 forms. Furthermore, due to their relatively simple technological handling and genetic and genetic engineering manipulation, they offer favorable conditions for the creation of biotransformation systems. The yeast cells can also be used as "recombinant cell factories" Yeast Saccharomyces cerevisiae has so far been used mainly for the functional heterologous expression of membrane-bound P450 forms from suckers, plants and eukaryotic microorganisms to high cell concentrations (high cell density fermentation) and used for biotransformation ADH1- Promotors (Oeda et al 1985 DNA 4 203-210) were a large number of different P450 forms (ER-standing and mitochondrial P450 isoforms) in S cerevisiae under the control of various strong promoters (ADH1, CUP1, PH05, GAL7, GAL10, GAL-CYC , PGK et al.) Functionally expanded (reviews by Yabusaki and Ohkawa 1991 In Frontiers in Biotransformation, Ruckpaul K, Rein H, eds, Vol 4, pp 87-126, Akademie Verlag, Berlin, Urban et al 1990 Biochemie 72 463- 472, Guengench et al 1991 Methods Enzymol 206 130, Schunck et al 1991 Eur J Cell Biol 55 336-345, Renaud et al 1993 Toxicology 22 39-52, Gonzalez and Korzekwa 1995 Annu Rev Pharmacol Toxicol 1995,35 369-390, Dumas et al 1996 Eur J Biochem 238 495-504, Pompon et al 1996 Methods Enzymol 272 51 -64, Pompon et al 1997 J Hepatol 26S2 81-85, Duport et al 1998 Nat Biotechnol 16 186-189)
Die Hefe S cerevisiae hat den Nachteil, daß die relativ geringen Konzentrationen und Aktivitäten der eigenen mikrosomalen Elektronentransportkomponenten (NADPH-P450 Reduktase, NADH-Cytochrome b5 Reduktase, Cytochrome b5) für die katalytische Aktivität hoher Konzentrationen eines heterologen P450 zum limitierenden Faktor werden können Es wurde deshalb mit unterschiedlichen Strategien und Erfolg versucht, die Effektivität des mikrosomalen Elektronentransfers auf das P450 zu erhohen - durch zusatzliche Expression der Gene von verschiedenen NADPH-P450 Reduktasen und in ausgewählten Fallen von Cytochrom b5 bzw durch Fusion der Reduktase- und P450 Strukturgene (Urban et al 1990 Biochemie 72 463-472, Sanglard et al 1990 Biocatalysis 4 19-28, Sakaki et al 1990 DNA Cell Biol 9 603- 614, Yabusaki und Ohkawa 1991 In Frontiers in Biotransformation, Ruckpaul K, Rein H, eds, Vol 4, pp 87-126, Akademie Verlag, Berlin, Urban et al 1993 Biochem Soc Trans 21 1028, Pompon et al Patent FR-PS-2679 249, Zimmer et al 1995 DNA Cell Biol 14 619-628, Zimmer et al 1995 Patent DE 19507546)The yeast S cerevisiae has the disadvantage that the relatively low concentrations and activities of its own microsomal electron transport components (NADPH-P450 reductase, NADH-cytochrome b 5 reductase, cytochrome b 5 ) can become a limiting factor for the catalytic activity of high concentrations of a heterologous P450 Therefore, different strategies and successes were attempted to increase the effectiveness of the microsomal electron transfer to the P450 - by additional expression of the genes of different NADPH-P450 reductases and in selected cases of cytochrome b 5 or by fusion of the reductase and P450 structural genes ( Urban et al 1990 Biochemie 72 463-472, Sanglard et al 1990 Biocatalysis 4 19-28, Sakaki et al 1990 DNA Cell Biol 9 603-614, Yabusaki and Ohkawa 1991 In Frontiers in Biotransformation, Ruckpaul K, Rein H, eds, Vol 4, pp 87-126, Akademie Verlag, Berlin, Urban et al 1993 Biochem Soc Trans 21 1028, Pompon et al Patent FR-PS-26 79 249, Zimmer et al 1995 DNA Cell Biol 14 619-628, Zimmer et al 1995 Patent DE 19507546)
Ein besonderer Nachteil von Saccharomyces Hefen ist die relativ geringe Aufnahmekapazitat bzw Aufnahmerate für lipophile Verbindungen wie Fettsauren und Alkane (Kohlwein und Paltauf 1984 Biochim Biophys Acta 792 310-317, Dell'Angeiica et al 1992 Comp Biochem Physiol 102B 261-265, Dell'Angeiica et al 1996 Biochem Mol biol Int 39 439-445) Die katalytischen Leistungen von heterologen P450 in S cerevisiae sind demzufolge meist gering, was offensichtlich mit einem unzureichenden Substrat- und Elektronentransport in dieser Hefe in Zusammenhang steht.A particular disadvantage of Saccharomyces yeasts is the relatively low absorption capacity or absorption rate for lipophilic compounds such as fatty acids and alkanes (Kohlwein and Paltauf 1984 Biochim Biophys Acta 792 310-317, Dell'Angeiica et al 1992 Comp Biochem Physiol 102B 261-265, Dell'Angeiica et al 1996 Biochem Mol biol Int 39 439-445) The catalytic performance of heterologous P450 in S cerevisiae is therefore usually low, which is evident from a insufficient substrate and electron transport in this yeast is related.
Deshalb wurden in jüngster Zeit neben S. cerevisiae auch andere Hefen als Wirte für die heterologe Expression von P450 getestet. Für die Hefe Kluyveromyces lactis wurde über die funktionelle Expression, jedoch mit geringer Aktivität, von P450scc und von Adrenodoxin unter Kontrolle des Lactasepromotors berichtet (Mencke et al. 1990. 19 th FEBS-Meeting, Budapest August 1990, Abstracts).Therefore, in addition to S. cerevisiae, other yeasts have recently been tested as hosts for the heterologous expression of P450. For the yeast Kluyveromyces lactis, functional expression, but with low activity, of P450 scc and of adrenodoxin under the control of the lactase promoter has been reported (Mencke et al. 1990, 19th th FEBS meeting, Budapest August 1990, abstracts).
In der methanolverwertenden Hefe Pichia pastohs gelang die funktionelle Expression des Cytochrom P450c17 (17α-hydroxylase/C17,20-lyase) aus einem Haifisch (Squalus acanthias) unter Kontrolle des AOX1 -Promotors (Tränt JM 1996 Arch Biochem Biophys 326:8-14). Für die Expression wird eine Kultivierung dieser Hefe auf Methanol benötigt. Das heterologe P450 zeigt jedoch eine relativ geringe spezifische Aktivität.In the methanol-utilizing yeast Pichia pastohs, the functional expression of the cytochrome P450c17 (17α-hydroxylase / C17.20-lyase) from a shark (Squalus acanthias) was controlled under the control of the AOX1 promoter (Tränt JM 1996 Arch Biochem Biophys 326: 8-14) . Cultivation of this yeast on methanol is required for expression. However, the heterologous P450 shows a relatively low specific activity.
Die alkanverwertenden Hefen, wie z.B. Candida maltosa, C. tropicalis oder Y. lipolytica, zeichnen sich durch eine hohe katalytische Aktivität ihrer eigenen P450 Systeme (in vivo Turnoverzahlen von 1-2 μmol/nmol P450 x min für die wirtseigenen alkaninduzierbaren P450) aus. Für die Hefen Y. lipolytica und C. maltosa sind gut entwickelte Wirts-Vektor-Systeme vorhanden (Übersichten in: Barth und Gaillardin 1996 Chapter 10 Yarrowia lipolytica In: Wolf K /Ed/ Non-conventional Yeasts in Biotechnology, Springer Verlag Berlin, pp 313-388; Barth und Gaillardin 1997 FEMS Microbiol Rev 19:219-237; Mauersberger et al. 1996 Chapter 12. Candida maltosa. In: Non-conventional Yeasts in Biotechnology, Wolf K, ed, Springer Verlag, Heidelberg, pp 411-580).The alkane-utilizing yeasts, e.g. Candida maltosa, C. tropicalis or Y. lipolytica, are characterized by a high catalytic activity of their own P450 systems (in vivo turnover numbers of 1-2 μmol / nmol P450 x min for the host's own alkane-inducible P450). Well-developed host-vector systems are available for the yeasts Y. lipolytica and C. maltosa (reviews in: Barth and Gaillardin 1996 Chapter 10 Yarrowia lipolytica In: Wolf K / Ed / Non-conventional Yeasts in Biotechnology, Springer Verlag Berlin, pp 313-388; Barth and Gaillardin 1997 FEMS Microbiol Rev 19: 219-237; Mauersberger et al. 1996 Chapter 12. Candida maltosa. In: Non-conventional Yeasts in Biotechnology, Wolf K, ed, Springer Verlag, Heidelberg, pp 411- 580).
Die Candida Hefen sind jedoch insgesamt durch ihre vom universellen genetischen Code abweichende Translation des Codons CUG als Serin anstelle von Leucin insgesamt keine gut geeigneten Wirte für die funktionelle heterologe Expression (Zimmer und Schunck 1995 Yeast 11 : 33-41 ; Sugiyame et al Yeast 11 : 43-52; Übersicht in Mauersberger et al. 1996 Chapter 12. Candida maltosa. In: Non- conventional Yeasts in Biotechnology, Wolf K, ed, Springer Verlag, Heidelberg, pp 411 -580). Das C. maltosa System ist deshalb nur für die Expression homologer P450 unter Kontrolle der homologen Promotoren GAL1-GAL10, PGK1 und ALK gut geeignet, nicht jedoch für die Expression heterologer Proteine (Ohkuma et al. 1995 Biochim Biophys Acta 1236: 163-169).However, due to their translation of the codon CUG as serine instead of leucine, which differs from the universal genetic code, the Candida yeasts are overall not very suitable hosts for the functional heterologous expression (Zimmer and Schunck 1995 Yeast 11: 33-41; Sugiyame et al Yeast 11: 43-52; overview in Mauersberger et al. 1996 Chapter 12. Candida maltosa. In: Non-conventional Yeasts in Biotechnology, Wolf K, ed, Springer Verlag, Heidelberg, pp 411 -580). The C. maltosa system is therefore only good for the expression of homologous P450 under the control of the homologous promoters GAL1-GAL10, PGK1 and ALK suitable, but not for the expression of heterologous proteins (Ohkuma et al. 1995 Biochim Biophys Acta 1236: 163-169).
Die alkanverwertende Hefe Y. lipolytica wurde in den zurückliegenden Jahren biochemisch, genetisch und molekularbiologisch sehr intensiv untersucht (Übersichten in Weber und Barth 1988, CRC Crit Rev Biotechnol 7: 281-337; Gaillardin und Heslot 1988 J Basic Microbiol 28: 161 -174; Barth und Gaillardin 1996 Chapter 10 Yarrowia lipolytica In: Wolf K /Ed/ Non-conventional Yeasts in Biotechnology, Springer Verlag Berlin, pp 313-388; Barth und Gaillardin 1997 FEMS Microbiol Rev 19:219- 237).The alkane-utilizing yeast Y. lipolytica has been intensively investigated biochemically, genetically and molecular biologically in the past years (reviews in Weber and Barth 1988, CRC Crit Rev Biotechnol 7: 281-337; Gaillardin and Heslot 1988 J Basic Microbiol 28: 161-174; Barth and Gaillardin 1996 Chapter 10 Yarrowia lipolytica In: Wolf K / Ed / Non-conventional Yeasts in Biotechnology, Springer Verlag Berlin, pp 313-388; Barth and Gaillardin 1997 FEMS Microbiol Rev 19: 219-237).
Es sind Transformationssysteme mit integrativen (Davidow et al. 1985 Curr Genet 10: 39-48; Gaillardin et al. 1985 Curr Genet 10: 49-58) und autonom replizierenden (Fournier et al. 1991 Yeast 7: 25-36, Fournier et al. 1993) Plasmiden bekannt. Für die Nutzung dieser Hefe zur heterologen Expression wurden neben dem gut untersuchten Expressionssystem mit dem XPR2-Promotor andere Vektoren mit regulierbaren starken Promotoren entwickelt, beispielsweise die Promotoren des Gens ICL1 der Isocitratlyase aus dem Glyoxylatzyklus (Barth und Scheuber 1993 Mol Gen Genet 241 : 422-430; Juretzek et al. 1995, Patent DE 195 25 282.9) und des Gens POT1 der Thiolase der peroxisomalen ß-Oxidation (Berninger et al. 1993 Eur J Biochem 216: 607-613). Bisher wurden eine Reihe von heterologen Proteinen in der Hefe Y. lipolytica exprimiert, wie z.B. der Blut-Gerinnungsfaktor Xllla des Menschen (Tharaud et al. 1992 Gene 121 : 111-119). Weitere Beispiele sind in Barth und Gaillardin 1996 (Chapter 10 Yarrowia lipolytica In: Wolf K /Ed/ Non-conventional Yeasts in Biotechnology, Springer Verlag Berlin, pp 313-388) sowie in Barth und Gaillardin 1997 (FEMS Microbiol Rev 19: 219-237) beschrieben.They are transformation systems with integrative (Davidow et al. 1985 Curr Genet 10: 39-48; Gaillardin et al. 1985 Curr Genet 10: 49-58) and autonomously replicating (Fournier et al. 1991 Yeast 7: 25-36, Fournier et al. 1993) plasmids are known. In addition to the well-studied expression system with the XPR2 promoter, other vectors with controllable strong promoters were developed for the use of this yeast for heterologous expression, for example the promoters of the ICL1 gene of isocitrate lyase from the glyoxylate cycle (Barth and Scheuber 1993 Mol Gen Genet 241: 422- 430; Juretzek et al. 1995, patent DE 195 25 282.9) and the gene POT1 of the thiolase of peroxisomal β-oxidation (Berninger et al. 1993 Eur J Biochem 216: 607-613). So far a number of heterologous proteins have been expressed in the yeast Y. lipolytica, e.g. the blood coagulation factor Xllla of humans (Tharaud et al. 1992 Gene 121: 111-119). Further examples are in Barth and Gaillardin 1996 (Chapter 10 Yarrowia lipolytica In: Wolf K / Ed / Non-conventional Yeasts in Biotechnology, Springer Verlag Berlin, pp 313-388) and in Barth and Gaillardin 1997 (FEMS Microbiol Rev 19: 219- 237).
Ein weiteres Problem stellt die Tatsache dar, daß natürliche high-copy Plasmide, wie sie in S. cerevisiae gefunden wurden, in Y. lipolytica nicht bekannt sind und nur artifizielle autonom replizierende low-copy Plasmide existieren. Die autonom replizierenden Plasmide vom Typ plNA237 (LEU2 CEN-ARS18) oder plNA443 (URA3 ARS68-CEN) tragen /ARS/CE/V-Sequenzen und kommen daher nur mit 1 -2 Kopien pro Zelle vor. Plasmide, die nur die /ARS-Sequenzen tragen, können mit mehreren Kopien pro Zelle vorkommen. Transformanden, die solche Plasmide tragen, sind aber relativ instabil und verlieren nach wenigen Generationswechseln diese Plasmide (Fournier et al. 1993 Proc Natl Acad Sei USA 90: 4912-4916). Plasmide, die ins Genom integriert werden, zeichnen sich auch unter nichtselektiven Kultivierungsbedingungen durch eine hohe Stabilität aus. Die bekannten Plasmide dieser Art werden in der Regel in die mutierten Gene Ieu2, Iys5, ura3 oder xpr2 [Locus: mutierte Gene LEU2, LYS5, URA3 oder XPR2] integriert und komplementieren die entsprechende Mutation. Diese Plasmide werden als eine Kopie ins Genom integriert.Another problem is the fact that natural high-copy plasmids as found in S. cerevisiae are not known in Y. lipolytica and only artificial, autonomously replicating low-copy plasmids exist. The autonomously replicating plasmids of the type plNA237 (LEU2 CEN-ARS18) or plNA443 (URA3 ARS68-CEN) carry / ARS / CE / V sequences and therefore only occur with 1-2 copies per cell. Plasmids carrying only the / ARS sequences can occur with multiple copies per cell. However, transformants carrying such plasmids are relative unstable and lose these plasmids after a few generation changes (Fournier et al. 1993 Proc Natl Acad Sei USA 90: 4912-4916). Plasmids that are integrated into the genome are characterized by high stability even under non-selective cultivation conditions. The known plasmids of this type are generally integrated into the mutated genes Ieu2, Iys5, ura3 or xpr2 [locus: mutated genes LEU2, LYS5, URA3 or XPR2] and complement the corresponding mutation. These plasmids are integrated into the genome as a copy.
Die als integrative multi-copy Plasmide geeigneten Vektoren tragen dagegen das Selektionsmarkergen URA3, dessen Promotorfunktion durch Deletion (URA3d) eingeschränkt ist. Eine Komplementation der entsprechenden ura3 Mutation wird erst durch eine erhöhte Kopiezahl pro Zelle erreicht.The vectors suitable as integrative multi-copy plasmids, on the other hand, carry the selection marker gene URA3, the promoter function of which is restricted by deletion (URA3d). The corresponding ura3 mutation is only complemented by an increased number of copies per cell.
Die ersten für Y. lipolytica beschriebenen integrativen multi-copy Plasmide plNA764 bis plNA774 (Le Dali et al. 1994 Curr Genet 26:38-44; Barth und Gaillardin 1996 Chapter 10 Yarrowia lipolytica In: Wolf K /Ed/ Non-conventional Yeasts in Biotechnology, Springer Verlag Berlin, pp 313-388; Barth und Gaillardin 1997 FEMS Microbiol Rev 19:219-237) werden in die chromosomalen repetitiven Sequenzen der ribosomalen DNA (rDNA G Einheit, Fournier et al. 1986 Gene 42:273-282) integriert. Als Selektionsmarkergen dient das Gen URA3d, dessen deletierte Promotorbereiche nur 41 bis 6 Basepaare "upstream" vom Startcodon ATG lang sind. Die durchschnittliche stabile Kopiezahl liegt zwischen 5 (plNA767) und 13 (plNA772) Kopien pro Zelle. Mit dem Plasmid plNA773 konnten ursprünglich 20-60 Kopien pro Zelle integriert werden. Ein entscheidender Nachteil dieser Plasmide ist, daß unter induzierenden und nichtselektiven Expressionsbedingungen keine stabilen Kopiezahlen erhalten werden konnten bzw. die integrierten Plasmidkopien verloren gingen. Ein weiterer Nachteil dieser Plasmide ist, die Verwendung des Plasmides pBR322 als Basisvektor für die Amplifikation in E. coli, was eine geringe Plasmidkopiezahl bedingt, die nur durch Zusatz von Chloramphenicol erhöht werden kann. Dadurch wird die Gewinnung der Plasmide aufwendiger und langwieriger.The first integrative multi-copy plasmids plNA764 to plNA774 described for Y. lipolytica (Le Dali et al. 1994 Curr Genet 26: 38-44; Barth and Gaillardin 1996 Chapter 10 Yarrowia lipolytica In: Wolf K / Ed / Non-conventional Yeasts in Biotechnology, Springer Verlag Berlin, pp 313-388; Barth and Gaillardin 1997 FEMS Microbiol Rev 19: 219-237) are incorporated into the chromosomal repetitive sequences of the ribosomal DNA (rDNA G unit, Fournier et al. 1986 Gene 42: 273-282) integrated. The URA3d gene, whose deleted promoter regions are only 41 to 6 base pairs "upstream" from the start codon ATG, serves as the selection marker gene. The average stable copy number is between 5 (plNA767) and 13 (plNA772) copies per cell. With plasmid plNA773, originally 20-60 copies per cell could be integrated. A decisive disadvantage of these plasmids is that no stable copy numbers could be obtained under inducing and non-selective expression conditions or the integrated plasmid copies were lost. A further disadvantage of these plasmids is the use of the plasmid pBR322 as a base vector for the amplification in E. coli, which requires a low number of plasmids, which can only be increased by adding chloramphenicol. This makes the extraction of the plasmids more complex and lengthy.
Eine andere Serie von integrativen Plasmiden (plNA970 - URA3d, ZETA, XPR2Pτo- XPR27e ermöglicht 5-15 Kopien pro Zelle; plNA1066 bzw. plNA1067 enthalten URASd'l bzw. URA3d4, sowie ZETA, XPR2Pro-XPR27e;; (Le Dali et al. 1995 Abstract "First Yarrowia lipolytica International Meeting" Paris-Grignon; Barth und Gaillardin 1996 Chapter 10 Yarrowia lipolytica In: Wolf K /Ed/ Non-conventional Yeasts in Biotechnology, Springer Verlag Berlin, pp 313-388) enthält das LTR-Element ZETA (long terminal repeat) des Retrotransposons Ylt1 von Y. lipolytica (EMBL X74146, Schmid-Berger et al. 1994 J Bacteriol 176:2477-2482) als Zielsequenz für die Integration ins Genom. Die Plasmide plNA1066 und plNA1067 (rDNA-Va anten plNA1064 und plNA1065) sind zur Expression von homologen und heterologen Proteinen unter Kontrolle des XP 2-Promotors geeignet. Diese Plasmide besitzen aber ebenfalls die gleichen Nachteile wie die Vektoren plNA776 bis plNA773. Weiterhin besitzen sie keine "Multiple cloning site". Die Komplettierung der Expressionskassette ist unter Nutzung der Schnittstellen Srfl, Apa\ und BglU möglich. Ein Austausch von Expressionskassetten zur Expression von Proteinen unter Kontrolle anderer Promotoren ist aber erst in mehreren Klonierungsschritten möglich. Daher ist es von großem Interesse, Plasmide zu entwickeln, die einen Austausch von DNA- Modulen (Expressionskassetten, Genbanken usw.) erlauben und zur multiplen Integration in das Genom geeignet sind.Another series of integrative plasmids (plNA970 - URA3d, ZETA, XPR2 Pτo - XPR2 7e enables 5-15 copies per cell; containing plNA1066 and plNA1067, respectively URASd'l or URA3d4, as well as ZETA, XPR2 Pro -XPR2 7e; ; (Le Dali et al. 1995 Abstract "First Yarrowia lipolytica International Meeting"Paris-Grignon; Barth and Gaillardin 1996 Chapter 10 Yarrowia lipolytica In: Wolf K / Ed / Non-conventional Yeasts in Biotechnology, Springer Verlag Berlin, pp 313-388) contains the LTR element ZETA (long terminal repeat) of the retrotransposon Ylt1 from Y. lipolytica (EMBL X74146, Schmid-Berger et al. 1994 J Bacteriol 176: 2477-2482) as the target sequence for integration into the genome. The plasmids plNA1066 and plNA1067 (rDNA variants plNA1064 and plNA1065) are suitable for the expression of homologous and heterologous proteins under the control of the XP 2 promoter. However, these plasmids also have the same disadvantages as the vectors pNA776 to pNA773. Furthermore, they have no "multiple cloning site". The expression cassette can be completed using the interfaces Srfl, Apa \ and BglU. An exchange of expression cassettes for the expression of proteins under the control of other promoters is only possible in several cloning steps. It is therefore of great interest to develop plasmids which allow an exchange of DNA modules (expression cassettes, gene banks, etc.) and are suitable for multiple integration into the genome.
Die Aufgabe besteht nun darin, ein neues, gut handhabbares System zur heterologen funktionellen Expression von Cytochrom P450 Genen in der Hefe Yarrowia lipolytica zur Verfügung zu stellen.The task now is to provide a new, easy-to-use system for the heterologous functional expression of cytochrome P450 genes in the yarrow Yarrowia lipolytica.
Erfindungsgemäß wird die Aufgabe durch rekombinante haploide oder diploide Y. lipolytica Zellen mit den im Anspruch 1 genannten Merkmalen gelöst. Vorteilhafte Ausstattungen der Zellen ergeben sich aus den abhängigen Unteransprüchen 2 bis 11.According to the invention the object is achieved by recombinant haploid or diploid Y. lipolytica cells with the features mentioned in claim 1. Advantageous configurations of the cells result from the dependent subclaims 2 to 11.
Die Erfindung wird weiterhin durch Plasmide zur Erzeugung rekombinanter haploider oder diploider Y. lipolytica Zellen mit den im Anspruch 12 genannten Merkmalen gelöst. Vorteilhafte Ausführungen der Plasmide ergeben sich aus den abhängigen Unteransprüchen 13 bis 19. Die Erfindung wird außerdem durch ein Verfahren zur Herstellung rekombinanter haploider oder diploider Y. lipolytica Zellen mit den im Anspruch 20 genannten Merkmalen gelöst. Vorteilhafte Varianten des Verfahrens ergeben sich aus den abhängigen Unteransprüchen 21 bis 23. Verwendungen der rekombinanten haploide oder diploide Y. lipolytica Zellen sind in den Ansprüchen 24 und 25 beschrieben.The invention is further solved by plasmids for the production of recombinant haploid or diploid Y. lipolytica cells with the features mentioned in claim 12. Advantageous designs of the plasmids result from the dependent subclaims 13 to 19. The invention is also achieved by a method for producing recombinant haploid or diploid Y. lipolytica cells with the features mentioned in claim 20. Advantageous variants of the method result from the dependent subclaims 21 to 23. Uses of the recombinant haploid or diploid Y. lipolytica cells are described in claims 24 and 25.
Mit der Bereitstellung von neuen low-copy und high-copy Plasmiden, geeignet zur autonomen Replikation oder zur multiplen Integration von Expressionskassetten, die unter Kontrolle eines regulierbaren Promotors (beispielsweise des ICL1 Gens, kodierend für die Isocitratlyase) der Hefe Y. lipolytica stehen, lassen sich rekombinante haploide oder diploide Y. lipolytica Zellen erzeugen. Überraschend wurde dabei festgestellt, daß diese Plasmide mit hoher Kopiezahl ins Genom integrieren und unabhängig von den Integrationsorten und Kultivierungsbedingungen stabil in Yarrowia // o/yf/ca-Transformanden erhalten werden können.With the provision of new low-copy and high-copy plasmids, suitable for autonomous replication or for the multiple integration of expression cassettes which are under the control of an adjustable promoter (for example the ICL1 gene, coding for the isocitrate lyase) of the yeast Y. lipolytica recombinant haploid or diploid Y. lipolytica cells are produced. It was surprisingly found that these plasmids integrate with a high copy number into the genome and can be obtained in Yarrowia // o / yf / ca transformants regardless of the integration sites and cultivation conditions.
Die so gewonnenen Zellen sind geeignet zur mikrobiellen Oxidation von hydrophoben Verbindungen und führen in einfacher Kultivierung der rekombinanten Hefen zu guten Ausbeuten des Oxidationsproduktes, insbesondere von Steroiden und anderen hydrophoben Verbindungen.The cells obtained in this way are suitable for the microbial oxidation of hydrophobic compounds and, by simple cultivation of the recombinant yeasts, lead to good yields of the oxidation product, in particular steroids and other hydrophobic compounds.
Die Hefe V. lipolytica wird durch Transformation mit neuen Expressionsvektoren (Expressionskassetten tragende Plasmide) in das Genom so verändert, daß Y. lipolytica Zellen in der Lage sind, durch einfache Kulturführung auf Medien mit geeigneter Kohlenstoffquelle zur funktionellen Expression von heterologen Proteinen, insbesondere Cytochrom P450 Enzymen, zu gelangen. Diese heterologen Cytochrom P450 Enzyme können in Y. lipolytica Zellen besser als in anderen bisher getesteten Hefen besonders effektiv zu mikrobiellen Stoffwandlungsprozessen eingesetzt werden.The yeast V. lipolytica is changed by transformation with new expression vectors (plasmids carrying expression cassettes) into the genome in such a way that Y. lipolytica cells are able, by simple culture control on media with a suitable carbon source, for the functional expression of heterologous proteins, in particular cytochrome P450 Enzymes to get. These heterologous cytochrome P450 enzymes can be used particularly effectively in microbial metabolism processes in Y. lipolytica cells better than in other yeasts tested to date.
Weiterhin werden durch die Plasmide gut handhabbare Vektoren zur Verfügung gestellt, die in hoher Kopiezahl stabil ins Genom der Hefe Y. lipolytica integriert werden können und dadurch die Erhöhung der Konzentration des heterolog zu exprimierenden Proteins erlauben. Ein besonderer Vorteil dieser Plasmide ist das Vorhandensein einer "Multiple cloning site", wodurch sich DNA-Module unterschiedlichster Art (Expressionskassetten) schnell und einfach in die Vektoren einsetzen lassen. Die Plasmide sind in die repetitiven Sequenzen von Y. lipolytica (LTR-Element ZETA, rDNA Cluster) integrierbar. Durch die Konstruktion geeigneter Plasmide zur multiplen Integration ins Genom von Y. lipolytica und die dadurch ermöglichte Erhöhung der Kopiezahl von Expressionskassetten mit regulierbaren starken Promotoren (beispielsweise ICL1- Promotor) wird die Aufgabe in vorteilhafter Weise gelöst.The plasmids also provide vectors which are easy to handle and which can be stably integrated into the genome of the yeast Y. lipolytica in high copy numbers and thereby allow the concentration of the protein to be expressed heterologously to be increased. A particular advantage of these plasmids is that The presence of a "multiple cloning site", so that different types of DNA modules (expression cassettes) can be inserted into the vectors quickly and easily. The plasmids can be integrated into the repetitive sequences of Y. lipolytica (LTR element ZETA, rDNA cluster). The task is solved in an advantageous manner by constructing suitable plasmids for multiple integration into the genome of Y. lipolytica and thereby increasing the number of copies of expression cassettes with controllable strong promoters (for example ICL1 promoter).
Verfahrensgemäß werden die Expressionskassetten zur heterologen Expression von Proteinen in Y. lipolytica, bestehend aus dem funktionell aktiven Promotor und Terminator (z.B. aus ICL1) und dem zu exprimierenden heterologen Genen, in autonom replizierende low-copy Plasmide oder integrative high-copy Plasmide überführt, in die Hefe transformiert und zur Expression gebracht.According to the method, the expression cassettes for the heterologous expression of proteins in Y. lipolytica, consisting of the functionally active promoter and terminator (for example from ICL1) and the heterologous genes to be expressed, are converted into autonomously replicating low-copy plasmids or integrative high-copy plasmids the yeast is transformed and expressed.
Die Aufgabe wird vorteilhaft durch Monooxygenasesysteme gelöst, die aus Cytochrom P450 und entsprechender NADPH-Cytochrom P450 Reduktase bestehen, welche in Y. lipolytica gleichzeitig exprimiert werden. Dabei kann eine homologe oder heterologe NADPH-Cytochrom P450 Reduktase auch unter Kontrolle eines geeigneten Promotors mit dem P450 co-exprimiert werden.The object is advantageously achieved by monooxygenase systems which consist of cytochrome P450 and corresponding NADPH-cytochrome P450 reductase, which are simultaneously expressed in Y. lipolytica. A homologous or heterologous NADPH cytochrome P450 reductase can also be co-expressed with the P450 under the control of a suitable promoter.
Die hydrophoben Verbindungen (Steroide und Derivate) werden in die Kulturlösung von derart gentechnisch veränderten Y. lipolytica Zellen gebracht, wodurch die exprimierten Enzyme eine selektive Hydroxylierung bewirken. Nach der Umsetzung werden die Hydroxylierungsprodukte abgetrennt. Die für die Erfindung genutzten Transformanden der Hefe Y. lipolytica können auf lang- und mittelkettigen n-Alkanen oder Ethanol für die Induktion der Expression der heterologen Gene kultiviert werden. Bevorzugte Enzymsysteme sind steroidhydroxylierende Cytochrom P450 Formen, eine NADPH-Cytochrom P450 Reduktase aus Y. lipolytica oder anderen Ursprungs. Überraschenderweise zeigen besonders die auf n-Alkan (Hexadecan) kultivierten rekombinanten Hefezellen im Vergleich mit auf Ethanol kultivierten Zellen die höchsten spezifischen Umsatzraten (pro Zelle oder pro Molekül P450 Enzym) für das Substrat Progesteron in 17α Hydroxy-Progesteron. Die hydrophoben Substrate, insbesondere Steroidverbindungen, werden erfindungsgemäß in Kulturen intakter Zellen (Zellsuspensionen) behandelt. Die zu hydroxylierenden Stoffe werden den Zellkulturen fein gemahlen oder in organischen Lösungsmitteln, z.B. Hexadecan oder Ethanol, gelöst zugesetzt. Das Verfahren wird bei niedrigen Temperaturen zwischen 28-32°C durchgeführt.The hydrophobic compounds (steroids and derivatives) are brought into the culture solution from such genetically modified Y. lipolytica cells, as a result of which the expressed enzymes bring about selective hydroxylation. After the reaction, the hydroxylation products are separated off. The transformants of the yeast Y. lipolytica used for the invention can be cultivated on long- and medium-chain n-alkanes or ethanol for the induction of the expression of the heterologous genes. Preferred enzyme systems are steroid hydroxylating cytochrome P450 forms, a NADPH cytochrome P450 reductase from Y. lipolytica or other origin. Surprisingly, the recombinant yeast cells cultured on n-alkane (hexadecane) in particular show the highest specific conversion rates (per cell or per molecule of P450 enzyme) for the substrate progesterone in 17α-hydroxy-progesterone in comparison with cells cultivated on ethanol. According to the invention, the hydrophobic substrates, in particular steroid compounds, are treated in cultures of intact cells (cell suspensions). The substances to be hydroxylated are finely ground to the cell cultures or added dissolved in organic solvents, for example hexadecane or ethanol. The process is carried out at low temperatures between 28-32 ° C.
Die Umsetzung von mindestens 0,22 g Substrat/L Zellkultur ist im Regelfall bereits nach 10 bis 30 Stunden Kulturführung weitgehend abgeschlossen. Der Abbruch der Reaktion erfolgt durch direkte Extraktion der Kulturflüssigkeit mit Isobutylmethylketon (MiBK) oder Dichlormethan (DCM) bzw. nach Ansäuerung mit verdünnter Schwefelsäure. Eine Kontrolle des Umsatzes kann mittels Chromatographie während der Kultivierungsdauer vorgenommen werden.The conversion of at least 0.22 g substrate / L cell culture is usually largely completed after 10 to 30 hours of culture. The reaction is terminated by direct extraction of the culture fluid with isobutyl methyl ketone (MiBK) or dichloromethane (DCM) or after acidification with dilute sulfuric acid. The conversion can be checked by means of chromatography during the cultivation period.
Inhalt der Erfindung sind rekombinante Yarrowia lipolytica Transformanden und die neuen Vektoren pBD64, p64zb, pBD67 und p67zb bzw. ihre Derivate mit einem Promotor p64ICLpro und p67ICLpro oder funktionsfähigen Expressionskassetten (beispielsweise p64IL43, p67IL43, p64IC17α oder p67IC17α), die zur multiplen Integration ins Genom von Y. lipolytica geeignet sind. Der Aufbau dieser Vektoren ist in Abb. 3-7 dargestellt.Contents of the invention are recombinant Yarrowia lipolytica transformants and the new vectors pBD64, p64zb, pBD67 and p67zb or their derivatives with a promoter p64ICLpro and p67ICLpro or functional expression cassettes (for example p64IL43, p67IL43, p64IC17α or p67IC17α) into the gene of multiple integration Y. lipolytica are suitable. The structure of these vectors is shown in Fig. 3-7.
Die Herstellung der rekombinanten Yarrowia //po/yfrca-Transformanden wird durch die Konstruktion einer Serie neuer Vektoren auf der Basis eines E. co//-Vektors mit Multipler cloning site vorteilhaft gelöst, die ein Markergen zur Selektion von multi-copy Transformanden und andere chromosomale DNA-Abschnitte von Y. lipolytica enthalten, welche zur multiplen Integration ins Genom der Hefe Y. lipolytica genutzt werden.The production of the recombinant Yarrowia // po / yfrca transformants is advantageously solved by the construction of a series of new vectors based on an E. co // vector with a multiple cloning site, which contains a marker gene for the selection of multi-copy transformants and others contain chromosomal DNA segments from Y. lipolytica, which are used for multiple integration into the genome of the yeast Y. lipolytica.
Diese Vektoren (Plasmidlinien) tragen als Selektionsmarker zur Amplifikation der Plasmid-DNA in E. coli das Ampicillin-Resistenzgen (ampR) und lassen sich durch ihre hohe Kopiezahl in hohen Ausbeuten aus E. coli leicht präparieren. Die Sequenzen zur Integration ins Genom der Hefe Y. lipolytica (rDNA, ZETA) und das Selektionsmarkergen URA3d4 werden durch Umklonierung aus den Plasmiden plNA1064 und plNA1067 (Abb. 2) gewonnen. DNA-Module, z.B. Expressionskassetten, lassen sich gut in die "Multiple cloning site" einklonieren. Die daraus resultierenden erfindungsgemaßen Basisplasmide pBD64 (rDNA) und pBD67 (LTR ZETA, Abb 3 und 4) lassen sich in einer vorteilhaften Ausgestaltung der Erfindung in wenigen Schritten leicht gewinnenThese vectors (plasmid lines) carry the ampicillin resistance gene (amp R ) as selection markers for the amplification of the plasmid DNA in E. coli and can be easily prepared from E. coli in high yields due to their high copy number. The sequences for integration into the genome of the yeast Y. lipolytica (rDNA, ZETA) and the selection marker gene URA3d4 are obtained by cloning from the plasmids plNA1064 and plNA1067 (Fig. 2). DNA modules, for example expression cassettes, can be cloned into the "multiple cloning site" well. The The resulting basic plasmids pBD64 (rDNA) and pBD67 (LTR ZETA, Figs. 3 and 4) according to the invention can be easily obtained in an advantageous embodiment of the invention in a few steps
In diese Basisplasmide lassen sich in die "Multiple cloning site" vorkonstruierte Expressionskassetten, bestehend aus einem starken und gut regulierbaren homologen Promotor (z B ICL 7-Promotor), einem heterologen Gen (z B lacZ oder CYP17) und einem homologen Terminator (z B ICL1 Terminator), leicht einfugen Die Expressionskassetten können außerdem nach Bedarf einfach gegen andere ausgetauscht werdenExpression cassettes preconstructed into the "multiple cloning site", consisting of a strong and easily regulated homologous promoter (eg ICL 7 promoter), a heterologous gene (eg lacZ or CYP17) and a homologous terminator (eg ICL1 terminator), easy to insert The expression cassettes can also be easily exchanged for others as required
Bei dem erfindungsgemaßen Verfahren werden diese neuen Plasmide (Expressionsvektoren) dann zur multiplen Integration der Expressionskassetten ins Genom (chromosomale Sequenzen der rDNA oder LTR ZETA) von V lipolytica eingesetzt Die damit erzeugten Transformanden weisen eine stabile Kopiezahl der Expressionskassetten (von etwa 10-14) auf Sie zeigen überraschender Weise im Vergleich mit autonom replizierenden Plasmiden (Kopiezahl 1 -2) eine deutlich höhere Expression heterologer Proteine, wie es am Beispiel des Reporterproteins ß-Galactosidase (lacZ Gen aus E coli, Abb 11 ) und des Cytochrom P45017α (CYP17 Gen des Rindes, Abb 13-14) gezeigt werden kannIn the method according to the invention, these new plasmids (expression vectors) are then used for the multiple integration of the expression cassettes into the genome (chromosomal sequences of the rDNA or LTR ZETA) from V lipolytica. The transformants produced in this way have a stable copy number of the expression cassettes (from about 10-14) Surprisingly, they show a significantly higher expression of heterologous proteins compared to autonomously replicating plasmids (copy number 1-2), as is the case for the reporter protein ß-galactosidase (lacZ gene from E coli, Fig. 11) and the cytochrome P45017α (CYP17 gene of the Beef, Fig. 13-14) can be shown
Eine für die Durchfuhrung der Erfindung wichtige Besonderheit besteht dann, daß die erhaltenen Transformanden mit einer hohen Kopiezahi der Expressionskassetten mit anderen Y lipolytica Stammen gekreuzt werden können Dadurch können vorteilhafte naturliche Merkmale eingekreuzt bzw die Expressionskassetten von mindestens zwei heterologen Genen in einem Wirt co-expπmiert werdenA special feature important for the implementation of the invention is that the transformants obtained can be crossed with other Y lipolytica strains with a high copy number of the expression cassettes. This enables advantageous natural traits to be crossed or the expression cassettes of at least two heterologous genes to be co-expressed in one host
Die dadurch erhaltenen diploiden Stamme zeichnen sich ebenfalls durch Stabilität der Expressionskassetten aus und sind überraschenderweise besonders gut zur P450 katalysierten Biotransformation wahrend des Wachstums auf n-Alkan und Ethanol geeignetThe diploid strains obtained in this way are also distinguished by the stability of the expression cassettes and, surprisingly, are particularly well suited to the P450-catalyzed biotransformation during growth on n-alkane and ethanol
Das erfindungsgemaße Verfahren mit rekombinanten Y lipolytica Zellen zeichnet sich durch hohe Hydroxylierungsraten aus So wird das Steroid Progesteron durch Y. lipolytica besser als mit bisher untersuchten rekombinanten Zellen von S. cerevisiae umgesetzt, die ebenfalls ein steroidhydroxylierendes P45017α exprimieren.The method according to the invention with recombinant Y lipolytica cells is distinguished by high hydroxylation rates. The steroid progesterone is characterized by Y. lipolytica better than with the previously investigated recombinant cells of S. cerevisiae, which also express a steroid hydroxylating P45017α.
Die Erfindung wird nachfolgend an Hand von Ausführungsbeispielen noch näher erläutert.The invention is explained in more detail below on the basis of exemplary embodiments.
Ausführungsbeispiel 1 :Example 1:
1. Verwendete Hefestämme und Vektoren1. Yeast strains and vectors used
Alle Stämme entstammen, wenn nicht anders angegeben, der Stammsammlung des Lehrstuhls für Allgemeine Mikrobiologie des Institutes für Mikrobiologie der Technischen Universität Dresden.Unless otherwise stated, all strains are from the strain collection of the Chair of General Microbiology at the Institute of Microbiology at the Technical University of Dresden.
Yarrowia lipolytica Stämme: B204-12A-213 (MATB Ieu2 ura3 leaky) PO1 d (MATA leu2-270 ura3-302 xpr2-322 SUC2)Yarrowia lipolytica strains: B204-12A-213 (MATB Ieu2 ura3 leaky) PO1 d (MATA leu2-270 ura3-302 xpr2-322 SUC2)
(Nicaud et al. 1989 Curr Genet 16:253-260) T4 PO1 d (p67IC17αT4), kurz T4 genannt: integrative Transformande T4 des Stammes PO1d mit dem im ZETA Element linearisierten Plasmid p67IC17α (URA3d4 ZETA), welche ca. 8-10 Kopien der Expressionskassette(Nicaud et al. 1989 Curr Genet 16: 253-260) T4 PO1 d (p67IC17αT4), or T4 for short: integrative transformants T4 of the strain PO1d with the plasmid p67IC17α (URA3d4 ZETA) linearized in the ZETA element, which is approx. 8-10 Copies of the expression cassette
ICL1Prol CYP171 ICL1jer zur heterologen Expression des Cytochrom P45017α des Rindes unter Kontrolle des Promotors und Terminators des ICL1 Gens von Y. lipolytica trägt. A1-5 (MATB met Alk+) Naturisolat. A15T4 (Alk+, prototroph) - diploider Stamm, entstanden durch Kreuzung der beiden Elternstämme A1-5 (MATB met' Alk*) PO1 d (p67IC17αT4) Saccharomyces cerevisiae: GRF18 (MATα his3-11 his3-15 leu2-3 Ieu2-112 canR)ICL1 Pro I CYP171 ICL1j he for heterologous expression of the cytochrome P45017α of the bovine under the control of the promoter and terminator of the ICL1 gene of Y. lipolytica. A1-5 (MATB with Alk + ) natural isolate. A15T4 (Alk + , prototrophic) - diploid strain, created by crossing the two parent strains A1-5 (MATB met ' Alk * ) PO1 d (p67IC17αT4) Saccharomyces cerevisiae: GRF18 (MATα his3-11 his3-15 leu2-3 Ieu2-112 can R )
E. coli/S. cere s/ae-Shuttle-Vektoren:E. coli / S. cere s / ae shuttle vectors:
YEp51 (Broach JR, Li Y-Y, Wu L-CC, Jayaram M, 1983, Vectors for high-level inducible expression of cloned genes in yeast. In: Experimental Manipulation of Gene Expression [Inoye M, ed], Academic Press New York, 83-117) enthalt das LEU2 Gen dieser Hefe als Selektionsmarker, den GAL1-GAL 7O-Promotor und Sequenzen aus dem 2μ Plasmid von S cerevisiae als Terminationsbereich und für die Gewährleistung hoher (50-100) Kopiezahlen dieser ARS-Plasmide YEp5117α (High-copy Plasmid, vgl Abb 9), CYP17 unter Kontrolle des sehr starken G/A/_7θ-Promotors, erhalten von Dr W -H Schunck (MDC Berlin-Buch) Literatur zum Wirts/Vektorsystem Schunck W-H et al 1991 Eur J Cell Biol 55 336-345, Zimmer T et al 1995 DNA Cell Biol 14 619-628YEp51 (Broach JR, Li YY, Wu L-CC, Jayaram M, 1983, Vectors for high-level inducible expression of cloned genes in yeast. In: Experimental Manipulation of Gene Expression [Inoye M, ed], Academic Press New York, 83-117) contains the LEU2 gene of this yeast as a selection marker, the GAL1-GAL 7O promoter and sequences from the 2μ plasmid of S cerevisiae as a termination area and for ensuring high levels (50-100) copy numbers of these ARS plasmids YEp5117α (high-copy plasmid, see Fig. 9), CYP17 under the control of the very strong G / A / _7θ promoter, obtained from Dr W -H Schunck (MDC Berlin-Buch) literature on the host / vector system Schunck WH et al 1991 Eur J Cell Biol 55 336-345, Zimmer T et al 1995 DNA Cell Biol 14 619-628
E coli/Y //po/yf/ca-Shuttle-Vektoren plNA237 - E coli/Y //po/yf/ca-Shuttle-Vektor plNA237 tragt neben der CEN-ARS18 Sequenz zur autonomen Rephkation in Y lipolytica das homologe EL/2-Gen sowie einen Anteil von pBR322 zur Amplifikation in E coli Die Kopiezahl dieses Vektors in Y lipolytica liegt bei 1 -3 pro Zelle (Fournier et al 1993 Proc Natl Acad Sei USA 90 4912-4916)E coli / Y // po / yf / ca shuttle vectors plNA237 - E coli / Y // po / yf / ca shuttle vector plNA237 carries the homologous EL / next to the CEN-ARS18 sequence for autonomous rephcation in Y lipolytica 2 gene and a portion of pBR322 for amplification in E coli The copy number of this vector in Y lipolytica is 1 -3 per cell (Fournier et al 1993 Proc Natl Acad Sei USA 90 4912-4916)
pYLI131D und plL43 (Juretzek et al 1995 Patent DE 195 25 282 A1 )pYLI131D and plL43 (Juretzek et al 1995 Patent DE 195 25 282 A1)
plNA1064 und plNA1067 (Abb 2) basieren auf dem E co//-Vektor pBR322 und tragen das multi-copy Selektionsmarkergen URA3d4 Der l/P43-Promotor besteht aus 8plNA1064 and plNA1067 (Fig. 2) are based on the E co // vector pBR322 and carry the multi-copy selection marker gene URA3d4. The l / P43 promoter consists of 8
Basenpaaren Das Plasmid plNA1064 tragt die rDNA-Sequenz für die integrative Transformation in die rDNA-Sequenz (G-Einheit) des Wirtes (Fournier et al 1986 Gene 42 273-282) Das Plasmid plNA1067 tragt die Sequenz des LTR ZETA (long terminal repeat) des Retrotransposon Ylt1 aus Y lipolytica (Le Dali et al 1995 Abstract "First Yarrowia lipolytica International Meeting" Pans-Gπgnon)Base pairs The plNA1064 carries the rDNA sequence for the integrative transformation into the host's rDNA sequence (G unit) (Fournier et al 1986 Gene 42 273-282). The plNA1067 carries the sequence of the LTR ZETA (long terminal repeat) of the retrotransposon Ylt1 from Y lipolytica (Le Dali et al 1995 abstract "First Yarrowia lipolytica International Meeting" Pans-Gπgnon)
Andere Vektoren pUCBM21 Boehnnger MannheimOther vectors pUCBM21 Boehnnger Mannheim
Verwendete DNA-SequenzenDNA sequences used
Die cDNA für das CYP17 wurde aus dem Plasmid pCMV17α (J Biol Chem 266 5898- 5904, 1991 ) gewonnen und kodiert für das Cytochrom P45017α der Nebenniere des Rindes. Dieses Plasmid wurde freundlicherweise von Prof. M. Waterman (Vanderbilt Universität Nashville) zur Verfügung gestellt.The cDNA for the CYP17 was obtained from the plasmid pCMV17α (J Biol Chem 266 5898-5904, 1991) and encoded for the cytochrome P45017α of the adrenal gland Beef. This plasmid was kindly provided by Prof. M. Waterman (Vanderbilt University Nashville).
Verwendete Medien: Minimalmedium (YNB): 0,67 oder 1 ,34% Yeast Nitrogen Base (Difco), 0,4 % NH CI, 0,3 mg/L FeCI3 Media used: Minimum medium (YNB): 0.67 or 1.34% Yeast Nitrogen Base (Difco), 0.4% NH CI, 0.3 mg / L FeCI 3
Minimalmedium (M) für die Kultivierung von Y. lipolytica im Fermenter (Scheller U et al. 1996 Methods Enzymol 272: 65-75).Minimal medium (M) for the cultivation of Y. lipolytica in the fermenter (Scheller U et al. 1996 Methods Enzymol 272: 65-75).
Zusätze von Aminosäuren (Leucin, Methionin, 30-50 mg/L) bzw. Uracil (50 mg/L) zur Komplementation der entsprechenden Mutationen je nach Bedarf für den Stamm. C-Quellen: 1 % Glucose, 1 % Ethanol, 1 % Hexadecan. Vollmedium: 1 % Yeast Extract, 1 % Bactopeptone, 2% Glucose. Für Plattenkultur wurden die obengenannten Medien mit 2% Agar-Agar hergestellt.Additions of amino acids (leucine, methionine, 30-50 mg / L) or uracil (50 mg / L) to complement the corresponding mutations as required for the strain. C sources: 1% glucose, 1% ethanol, 1% hexadecane. Complete medium: 1% yeast extract, 1% bactopeptone, 2% glucose. For plate culture, the above media were made with 2% agar.
Ausführungsbeispiel 2:Example 2:
2. Nachweis der repetitiven Sequenzen rDNA und ZETA in verschiedenen Yarrowia //po/yf/ca-Stämmen (Abb 1 ) und Transformationseffizienzen zur Integration ins Genom2. Detection of the repetitive sequences rDNA and ZETA in different Yarrowia // po / yf / ca strains (Fig. 1) and transformation efficiencies for integration into the genome
Zur Darstellung der repetitiven Sequenzen rDNA und ZETA in verschiedenen Yarrowia //po/yf/ca-Stämmen wurden die Stämme H222 (Wildtyp), B512-3, B204-12A-213, B204- 12C, PO1 d, E150 und E129 mit dem Restriktionsenzym EcoRI hydrolysiert und gelelektrophoretisch aufgetrennt. Die DNA wurde auf Nitrocellulose transferiert und mit folgenden Sonden beprobt: Nachweis ZETA-Sequenz mit ZETA-Fragment aus pBD67 (Abb. 3) und Nachweis rDNA mit rDNA-Fragment aus pBD64 (Abb. 3). Dabei zeigte sich überraschenderweise, daß in den Stämmen PO1d und H222 keine ZETA- Sequenzen nachgewiesen werden konnten (Abb. 1 ). Trotz der fehlenden ZETA- Sequenzen lassen sich die Plasmide mit der ZETA-Sequenz ins Genom vielfach integrieren (Abb. 8).To display the repetitive sequences rDNA and ZETA in different Yarrowia // po / yf / ca strains, the strains H222 (wild type), B512-3, B204-12A-213, B204-12C, PO1 d, E150 and E129 were used with the Restriction enzyme EcoRI hydrolyzed and separated by gel electrophoresis. The DNA was transferred to nitrocellulose and sampled with the following probes: detection of ZETA sequence with ZETA fragment from pBD67 (FIG. 3) and detection of rDNA with rDNA fragment from pBD64 (FIG. 3). It was surprisingly found that no ZETA sequences could be detected in the strains PO1d and H222 (Fig. 1). Despite the lack of ZETA sequences, the plasmids with the ZETA sequence can be integrated into the genome in many ways (Fig. 8).
Ausführungsbeispiel 3:Example 3:
3. Konstruktion der Plasmide pBD64 und pBD67 (Abb 3)3. Construction of plasmids pBD64 and pBD67 (Fig. 3)
Der E co//-Vektor pUCBM21 wurde mit der Restriktionsendonuklease Λ/del vollständig verdaut. Die einzelsträngigen Enden der verdauten DNA wurden mit Polymerase I (Klenow-Fragment) aufgefüllt. Die DNA wurde mit ßamHI nachgespalten. Der so vorbereitete Vektor wurde jeweils mit den EcoRI/ßamHI-Fragmenten aus den Vektoren plNA1064 (3178 bp) bzw. plNA1067 (2423 bp) ligiert. Dazu wurden die Vektoren plNA1064 und 1067 (Abb. 2) mit EcoRI verdaut und die einzelsträngigen Enden mit dem Klenow-Fragment aufgefüllt. Anschließend wurde die DNA mit ßamHI verdaut. Die resultierenden Vektoren sind die Plasmide pBD64 (mit rDNA als Target-Sequenz) und pBD67 (mit ZETA-Element als Target-Sequenz) (Abb. 3). Diese Plasmide waren nun geeignet, DNA-Fragmente (z.B. Expressionskassetten) in die "Multiple cloning site" aufzunehmen.The E co // vector pUCBM21 was completely digested with the restriction endonuclease Λ / del. The single-stranded ends of the digested DNA were treated with polymerase I (Klenow fragment) padded. The DNA was cleaved with ßamHI. The vector prepared in this way was ligated in each case with the EcoRI / βamHI fragments from the vectors plNA1064 (3178 bp) and plNA1067 (2423 bp). For this, the vectors pNA1064 and 1067 (Fig. 2) were digested with EcoRI and the single-stranded ends were filled in with the Klenow fragment. The DNA was then digested with ßamHI. The resulting vectors are the plasmids pBD64 (with rDNA as the target sequence) and pBD67 (with ZETA element as the target sequence) (FIG. 3). These plasmids were now suitable for incorporating DNA fragments (eg expression cassettes) into the "multiple cloning site".
Ausführungsbeispiel 4Embodiment 4
4. Konstruktion der Vektoren p64ICLpro und p67ICLpro (Abb. 5)4. Construction of the vectors p64ICLpro and p67ICLpro (Fig. 5)
Für die Konstruktion der Plasmide p64ICLpro und p67ICLpro (tragen ICL 7-Promotor) wurden die Plasmide pBD64, pBD67 und pYLI131 D (Juretzek et al. 1997 DE 195 25 282 A1 ) mit den Resthktionsendonukleasen ßamHI und Kpnl verdaut. Das den ICL1- Promotor enthaltende 2162 bp große ßamHI/ pni-Fragment wurde mit den pnl/ßamHI geöffneten Plasmiden pBD64 und pBD67 ligiert. Die resultierenden Vektoren waren p64ICLpro und p67ICLpro. Diese Plasmide enthalten den ICL1- Promotor (Abb. 5).For the construction of the plasmids p64ICLpro and p67ICLpro (carry ICL 7 promoter), the plasmids pBD64, pBD67 and pYLI131 D (Juretzek et al. 1997 DE 195 25 282 A1) were digested with the residual endonucleases ßamHI and Kpnl. The 2162 bp ßamHI / pni fragment containing the ICL1 promoter was ligated with the pnl / ßamHI opened plasmids pBD64 and pBD67. The resulting vectors were p64ICLpro and p67ICLpro. These plasmids contain the ICL1 promoter (Fig. 5).
Ausführungsbeispiel 5Embodiment 5
5. Konstruktion der Vektoren p64IL43 und p67IL43 zur heterologen Expression von ß Galactosidase (/acZ-Gen) aus E. coli (Abb. 6)5. Construction of the vectors p64IL43 and p67IL43 for the heterologous expression of β-galactosidase (/ acZ gene) from E. coli (Fig. 6)
Für die Konstruktion der Vektoren p64IL43 und p67IL43 wurden die Plasmide p64ICLpro und p67ICLpro mit ßamHI verdaut und anschließend dephosphoryliert. Aus dem Plasmid plL43 (Juretzek et al. 1995 DE 195 25 282 A1 ) wurde das 3833 bp große ßamHI-Fragment isoliert und mit den geöffneten Vektoren ligiert. Die resultierenden Plasmide waren p64IL43 und p67IL43 (Abb. 6) und enthalten die Expressionskassette /C -/-Promotor//acZ-Gen//C /-Terminator.For the construction of the vectors p64IL43 and p67IL43, the plasmids p64ICLpro and p67ICLpro were digested with ßamHI and then dephosphorylated. The 3833 bp βamHI fragment was isolated from the plasmid plL43 (Juretzek et al. 1995 DE 195 25 282 A1) and ligated to the opened vectors. The resulting plasmids were p64IL43 and p67IL43 (Fig. 6) and contain the expression cassette / C - / - promoter // acZ gene // C / terminator.
Ausführungsbeispiel 6Embodiment 6
6. Konstruktion der Vektoren p64IC17α und p67IC17α zur heterologen6. Construction of the vectors p64IC17α and p67IC17α to the heterologous
Expression von Cytochrom P45017α aus der Nebennierenrinde des Rindes Die Klonierung der Expressionskassette für die heterologe Expression von CYP17 (Rind) unter Kontrolle des ICL 1 -Promotors wurde in mehreren Teilschritten, durch Umklonierung der CYP17-cDNA in den Vektor pYLI131 D und durch Amplifizierung von DNA, die die korrekte Fusion des CYP17 ORF an den ICL 7-Promotor ermöglicht, realisiert. Dazu wurde der für den C-Terminus kodierende Teil der CYP17 cDNA aus dem Vektor YEp5117α (Abb. 9) als /-//ndlll/ßg/ll-Fragment gemeinsam mit dem ICL1- Terminator-Fragment ßamHi/H ndlll in den ßamHI/ßg/ll geöffneten Vektor pYLI131 D ligiert (Vorkonstrukt). Die Expressionskassette wurde komplettiert durch Einfügen des ßg/ll-PCR-Fragmentes, welches mittels einer Zweischritt-rekombinanten PCR erzeugt wurde. Im ersten Schritt wurden separat das ICL 7-Promotor/lntron- und das CYP17- Fragment von den Plasmiden pYLI131 D bzw. YEp5117α mit folgenden Oiigonukleotiden amplifiziert. Amplifizierung ICL 7-Promotor/ Intronfragment: Primer 1 , 5'-TAGATCTGGGGATCCCCAGTAGACTGACCAAGC-3'; Primer 2, 5'-CACTGGGTTAGTACGGG-3'. Amplifizierung des CYP17-Fragmentes:Expression of cytochrome P45017α from the bovine adrenal cortex The cloning of the expression cassette for the heterologous expression of CYP17 (bovine) under the control of the ICL 1 promoter was carried out in several partial steps, by recloning the CYP17 cDNA into the vector pYLI131 D and by amplifying DNA which indicated the correct fusion of the CYP17 ORF enables the ICL 7 promoter. For this purpose, the part of the CYP17 cDNA coding for the C-terminus was extracted from the vector YEp5117α (Fig. 9) as / - // ndlll / ßg / II fragment together with the ICL1 terminator fragment ßamHi / H ndlll in the ßamHI / ßg / ll opened vector pYLI131 D ligated (preconstruct). The expression cassette was completed by inserting the ßg / ll PCR fragment, which was generated by means of a two-step recombinant PCR. In the first step, the ICL 7 promoter / intron and the CYP17 fragment from the plasmids pYLI131 D and YEp5117α were amplified separately with the following oligonucleotides. Amplification ICL 7 promoter / intron fragment: Primer 1, 5'-TAGATCTGGGGATCCCCAGTAGACTGACCAAGC-3 '; Primer 2, 5'-CACTGGGTTAGTACGGG-3 '. Amplification of the CYP17 fragment:
Primer 3, 5'-CCCGTACTAACCCAGTGTGGCTGCTCCTGGCTG-3'; Primer 4, 5'-TTATGTTGGTCACCGCC-3'. Im zweiten Schritt wurden die Fragmente an sich überlappenden Sequenzen rekombiniert und mit Primer 1 und 4 amplifiziert. Das rekombinierte PCR-Produkt wurde als ßgr/ll-Fragment in das Vorkonstrukt eingesetzt und der autonom replizierende low-copy Vektor plC17α (Abb. 9) erhalten. Durch Umklonierung als ul/ pnl-Fragment in die Vektoren p64IL43 oder p67IL43 (Abb. 6) wurden die Vektoren p64IC17α bzw. p67IC17α (Abb. 9) erhalten.Primer 3, 5'-CCCGTACTAACCCAGTGTGGCTGCTCCTGGCTG-3 '; Primer 4, 5'-TTATGTTGGTCACCGCC-3 '. In the second step, the fragments were recombined at overlapping sequences and amplified with primers 1 and 4. The recombined PCR product was inserted into the preliminary construct as a βgr / II fragment and the autonomously replicating low-copy vector plC17α (FIG. 9) was obtained. The vectors p64IC17α and p67IC17α (Fig. 9) were obtained by cloning as an ul / pnl fragment into the vectors p64IL43 or p67IL43 (FIG. 6).
Ausführungsbeispiel 7Embodiment 7
7. Konstruktion der Vektoren p64zb und p67zb7. Construction of the vectors p64zb and p67zb
Die Vektoren pBD64 und pBD67 wurden mit der Restriktionsendonuklease Hind\\\ partiell hydrolysiert, mit dem Enzym Klenow-Fragment die freien DNA-Enden aufgefüllt und religiert. Die Plasmide mit einem /-//ndlll-Ort in der Multiple cloning site wurden isoliert und mit H/ndlll erneut hydrolysiert. Die linearisierten Fragmente wurden dephosphoryliert und mit nachfolgend beschriebenen H/'ndlll-verdauten PCR- Fragmenten ligiert. Die korrektorientierten Vektoren p64zb und p67zb wurden isoliert. Das PCR-Fragment zur Insertion in den Vektor pBD64 wurde von dem selbigen Plasmid mit den Oligonukleotiden 5'-attaagcttcggtatgataggaagag-3' und 5'-tggaagcttgggagaccccaagg-3' amplifiziert. Unter Nutzung der Oligonukleotide 5'-tgtaagcttcgtacgggagagttagtcatccgac-3' und 5'-aagaagcttaagggaggtgtcctgttccac-3' wurde vom Plasmid pBD67 das PCR-Fragment zur Insertion in den Vektor pBD67 synthetisiert.The vectors pBD64 and pBD67 were partially hydrolyzed with the restriction endonuclease Hind \\\, the free DNA ends were filled in with the enzyme Klenow fragment and religated. The plasmids with a / - // ndlll site in the multiple cloning site were isolated and hydrolyzed again with H / ndlll. The linearized fragments were dephosphorylated and ligated with H / ' ll digested PCR fragments described below. The corrective vectors p64zb and p67zb were isolated. The PCR fragment for insertion into the vector pBD64 was amplified from the same plasmid with the oligonucleotides 5'-attaagcttcggtatgataggaagag-3 'and 5'-tggaagcttgggagaccccaagg-3'. Using the oligonucleotides 5'-tgtaagcttcgtacgggagagttagtcatccgac-3 'and 5'-aagaagcttaagggaggtgtcctgttccac-3' the plasmid pBD67 was used to synthesize the PCR fragment for insertion into the vector pBD67.
Durch Insertion von Expressionskassetten in die Multiple cloning site muß der dritte Λ/of1-Ort (Plasmid p67zb) bzw. Sacll-Ort (Plasmid p64zb) eliminiert werden, da durch Hydrolyse mit den jeweiligen Enzymen die Abtrennung der E. co//-haltigen DNA erfolgt.The third Λ / of1 site (plasmid p67zb) or Sacll site (plasmid p64zb) must be eliminated by inserting expression cassettes into the multiple cloning site since hydrolysis with the respective enzymes involves the separation of the E. co // - containing DNA is done.
Ausführungsbeispiel 8Embodiment 8
8. Integrative Transformation von Y. lipolytica PO1d und Bestimmung der integrierten Expressionskassetten.8. Integrative transformation of Y. lipolytica PO1d and determination of the integrated expression cassettes.
Zur integrativen Transformation in Y lipolytica wurden kompetente Zellen erzeugt und mit linearisierter Plasmid-DNA (0,2-1 μg) und Carrier-DNA (2-5 μg) transformiert. Dazu wurde das Plasmid p64IL43 mit dem Restriktionsenzym Sacll und das Plasmid p67IL43 mit Λ/ofl vollständig verdaut (siehe Abb. 6). Die Ura+ Transformanden wurden nach 4 bis 14 Tagen auf Agar-Selektionsmedium erhalten. Die dabei erreichte Transformationseffizienz lag zwischen 3 und 50 Transformanden pro μg Plasmid-DNA (Methoden nach Barth und Gaillardin 1996 The dimorphic fungus Yarrowia lipolytica. In Nonconventional Yeasts in Biotechnology, Wolf K, ed, Springer Verlag, Heidelberg, pp 313-388).For integrative transformation in Y lipolytica, competent cells were generated and transformed with linearized plasmid DNA (0.2-1 μg) and carrier DNA (2-5 μg). For this purpose, plasmid p64IL43 was completely digested with the restriction enzyme SacII and plasmid p67IL43 with Λ / ofl (see Fig. 6). The Ura + transformants were obtained after 4 to 14 days on agar selection medium. The transformation efficiency achieved was between 3 and 50 transformants per μg of plasmid DNA (methods according to Barth and Gaillardin 1996 The dimorphic fungus Yarrowia lipolytica. In Nonconventional Yeasts in Biotechnology, Wolf K, ed, Springer Verlag, Heidelberg, pp 313-388).
Zur Bestimmung der Kopiezahl der ins Genom integrierten Expressionskassetten wurde die Total-DNA der untersuchten Transformanden isoliert und vollständig mit ßamHI verdaut. Die so gewonnene DNA wurde gelelektrophoretisch in 0,8 % Agarose aufgetrennt und auf Nylonmembran geblottet. Zur Southern-Hybridisierung wurde als Sonde 32P-radioaktivmarkierte DNA des bekannten ICL 7-lntrons aus Y. lipolytica eingesetzt. Die Verteilung der Radioaktivität und deren Intensität wurde mittels Phosphorimager "Storm" (MD) analysiert. Die Kopiezahl wurde aus dem Verhältnis der Intensität der 3833 bp Bande (integrierte /acZ-Expressionskassette) und der 2281 bp-Bande (chromosomales homologes ICL1 -Gen) ermittelt. Die ermittelten Kopiezahlen lagen zwischen 4 und 38 Kopien pro Zelle (Abb. 10). Die durchschnittliche Kopiezahl liegt bei 10 bis 14 Kopien pro Zelle. Transformanden mit geringerer Kopiezahl wuchsen langsamer als der Wildtyp. Transformanden mit durchschnittlicher oder höherer Kopiezahl wuchsen vergleichbar schnell zum Wildtyp.To determine the number of copies of the expression cassettes integrated into the genome, the total DNA of the investigated transformants was isolated and completely digested with ßamHI. The DNA obtained in this way was separated by gel electrophoresis in 0.8% agarose and blotted on a nylon membrane. For Southern hybridization, 32 P-radioactively labeled DNA of the known ICL 7 intron from Y. lipolytica was used as the probe. The distribution of the radioactivity and its intensity was analyzed by means of the phosphorimager "Storm" (MD). The copy number was determined from the ratio of the intensity of the 3833 bp band (integrated / acZ expression cassette) and the 2281 bp band (chromosomal homologous ICL1 gene). The number of copies found was between 4 and 38 copies per cell (Fig. 10). The average number of copies is 10 to 14 copies per cell. Transformants with lower number of copies grew more slowly than the wild type. Transformants with average or higher number of copies grew comparatively quickly to the wild type.
Ausführungsbeispiel 9 9. Expression der ß-Galactosidase-Aktivität von multi-copy TransformandenEmbodiment 9 9. Expression of the β-galactosidase activity of multi-copy transformants
Zur Bestimmung der Expression der ß-Galactosidase unter Kontrolle des induzierbaren ICL1 -Promotors wurden die Transformanden auf Selektionsmedium mit Glucose für 28 h bei 28°C vorkultiviert und nach zweimaligem Waschen mit Medium ohne C-Quelle auf Selektionsmedium mit Ethanol zur Bildung der ß-Galactosidase umgesetzt. Die optische Dichte (OD6oo) zum Start der Induktion lag bei 0,7-1. Zur Bestimmung der spezifischen ß-Galactosidase-Aktivität wurden alle 30 Minuten über 13 Stunden Proben entnommen (Reynolds und Lundblad 1994 In: Current Protocols in Molecular Biology, Ausubel et al. /Eds/ J Wiley, New York, Vol 2, Unit 13.6.1 ). Als Vergleich wurde die Expression der ß-Galactosidase mit dem low-copy Expressionssystem plL43 (Juretzek et al. 1995 D195 25 282 A1 ) im Stamm PO1 d bestimmt (Abb. 11 ).To determine the expression of the β-galactosidase under the control of the inducible ICL1 promoter, the transformants were pre-cultivated on selection medium with glucose for 28 h at 28 ° C. and after washing twice with medium without a C source on selection medium with ethanol to form the β-galactosidase implemented. The optical density (OD 6 oo) at the start of the induction was 0.7-1. To determine the specific ß-galactosidase activity, samples were taken every 30 minutes for 13 hours (Reynolds and Lundblad 1994 In: Current Protocols in Molecular Biology, Ausubel et al. / Eds / J Wiley, New York, Vol 2, Unit 13.6. 1 ). As a comparison, the expression of the β-galactosidase was determined using the low-copy expression system plL43 (Juretzek et al. 1995 D195 25 282 A1) in the strain PO1 d (Fig. 11).
Ausführungsbeispiel 10Embodiment 10
10. Bestimmung der Stabilität von Transformanden Zur Ermittlung der Stabilität wurden Transformanden in nichtselektivem Vollmedium (YPD), in Minimalmedium YNB mit Uracil und Glucose sowie in Minimalmedium mit Uracil und Ethanol über 20 Generationen kultiviert. Die Kopiezahlen wurden wie unter Punkt 5 bestimmt. Die getesteten Transformanden trugen nach 20 Generationen vergleichbar viele Kopien wie die Ausgangstransformanden. Transformanden mit 10 bis 14 Kopien pro Zelle wachsen normal und die Kopiezahlen sind in der Zellpopulation stabil.10. Determination of the stability of transformants To determine the stability, transformants were cultivated in non-selective full medium (YPD), in minimal medium YNB with uracil and glucose and in minimal medium with uracil and ethanol over 20 generations. The number of copies was determined as in point 5. After 20 generations, the tested transformants carried as many copies as the original transformants. Transformants with 10 to 14 copies per cell grow normally and the copy numbers are stable in the cell population.
Ausführungsbeϊspiel 11Implementation example 11
11. Vergleich der Cytochrom P45017α Aktivität nach heterologer Expression in Y. lipolytica ( Abb. 13 und Abb. 14)11. Comparison of the cytochrome P45017α activity after heterologous expression in Y. lipolytica (Fig. 13 and Fig. 14)
Zur Bestimmung der spezifischen Aktivität von heterolog exprimiertem Cytochrom P45017α in Y. lipolytica oder in S. cerevisiae wurden die Zellen im Schüttelkolben in Minimalmedium (M) mit induzierenden und nicht induzierenden C-Quellen kultiviert. Zum Zeitpunkt des Startes der Hauptkultur und alle 3 h über 25 h wurden Proben entnommen und die OD6oo durch Zugabe des entsprechenden Mediums auf eine OD6oo von 2 bis 4 eingestellt. Zu 1 ml dieser Verdünnung wurden 100 nmol 3H-Progesteron (gelöst in Ethanol) zugesetzt und die Kulturen für 30 min bzw. 60 min bei 28°C, 240 U/min im Schüttelinkubator kultiviert. Der Ansatz wurde mit 2 ml Dichlormethan extrahiert und die organische Phase gewonnen, eingedampft und in 100 μl Chloroform/ Essigsäureethylester (3:1 , Laufmittel) aufgenommen. Die Proben wurden dünnschichtchromatographisch auf Kieselgelplatten aufgetrennt und die Verteilung der Radioaktivität bestimmt. Die Ergebnisse sind in Abb. 12 und Abb. 14 dargestellt.To determine the specific activity of heterologously expressed cytochrome P45017α in Y. lipolytica or in S. cerevisiae, the cells in the shake flask were in Minimal medium (M) cultivated with inducing and non-inducing C sources. At the time of starting the main culture and every 3 h for 25 h, samples were taken and the OD 6 oo was adjusted to an OD 6 oo of 2 to 4 by adding the appropriate medium. 100 nmol of 3 H-progesterone (dissolved in ethanol) were added to 1 ml of this dilution and the cultures were cultured in a shaking incubator at 28 ° C. and 240 rpm for 30 min and 60 min, respectively. The mixture was extracted with 2 ml of dichloromethane and the organic phase was recovered, evaporated and taken up in 100 μl of chloroform / ethyl acetate (3: 1, eluent). The samples were separated by thin layer chromatography on silica gel plates and the distribution of radioactivity was determined. The results are shown in Fig. 12 and Fig. 14.
Ausführungsbeispiel 12Embodiment 12
12. Gewinnung des diploiden rekombinanten Stammes (A15T4), Fermentation von A15T4 auf Hexadecan, Biotransformation von Progesteron (Abb. 15) Der diploide Stamm A15T4 wurde durch Kreuzung der Stämme A1-5 und T4 erzeugt (Diploidisierung nach Barth und Gaillardin 1996) The dimorphic fungus Yarrowia lipolytica. in: Nonconventional Yeasts in Biotechnology, Wolf K, ed, Springer Verlag, Heidelberg, pp 313-388). Dieser Stamm wurde zur Umsetzung von Progesteron zu 17α-Hydroxprogesteron im 1 -Liter-Bioreaktor eingesetzt (Abb. 15).12. Obtaining the diploid recombinant strain (A15T4), fermentation of A15T4 on hexadecane, biotransformation of progesterone (Fig. 15) The diploid strain A15T4 was generated by crossing the strains A1-5 and T4 (diploidization according to Barth and Gaillardin 1996) The dimorphic fungus Yarrowia lipolytica. in: Nonconventional Yeasts in Biotechnology, Wolf K, ed, Springer Verlag, Heidelberg, pp 313-388). This strain was used to convert progesterone to 17α-hydroxprogesterone in a 1 liter bioreactor (Fig. 15).
Medienzusammensetzung:Media composition:
Minimalmedium (M) für die Kultivierung von Y. lipolytica im Fermenter (Scheller U et al. Methods in Enzymology 272: 65-75 1996).Minimal medium (M) for the cultivation of Y. lipolytica in the fermenter (Scheller U et al. Methods in Enzymology 272: 65-75 1996).
Fermentationsparameter:Fermentation parameters:
Volumen 1 Liter Arbeitsvolumen Temperatur 28°C Rührung 750 - 1000 U/min pH-Wert 4,60, Regelung durch Zugabe von ca. 2M NaOHVolume 1 liter working volume temperature 28 ° C stirring 750 - 1000 rpm pH 4.60, regulation by adding approx. 2M NaOH
Belüftung 1 - 2 vvm zur Gewährleistung von 30-100% O2-Sättigung Antischaum Antifoam 289 (SIGMA A5551 ) Kulturverlauf:Ventilation 1 - 2 vvm to ensure 30-100% O 2 saturation Antifoam Antifoam 289 (SIGMA A5551) Cultural history:
1 Liter-Hauptkultur im Fermenter1 liter main culture in the fermenter
1. Vorkultur - 10 ml M (1 % Glucose)1st preculture - 10 ml M (1% glucose)
2. Vorkultur - 100 ml M (1 % Glucose) Start der Hauptkultur2. Pre-culture - 100 ml M (1% glucose) Start the main culture
Variante A 1 ) 900 ml M (0,2% Glucose) - Start mit 100 ml 2. Vorkultur Start-ODeoo ca. 1 -1 ,5Variant A 1) 900 ml M (0.2% glucose) - Start with 100 ml 2nd preculture Start-ODeoo approx. 1 -1.5
2) Wachstum auf Glucose bis zum Glucoseverbrauch (nach ca. 6-8 h), bei OD6oo von ca. 5 angezeigt durch Stop der Säuerung bzw. leichten pH- Anstieg)2) Growth on glucose until consumption of glucose (after approx. 6-8 h), at OD 6 oo of approx. 5 indicated by stop of acidification or slight increase in pH)
3) Zugabe von 1 % Hexadecan (autoklaviert)3) Add 1% hexadecane (autoclaved)
4) Beginn Verwertung von Hexadecan nach ca. 1-2 h Zugabe von 0,05% Progesteron mit 1 % DMF (0,5 g Progesteron in 10 ml DMF)4) Start utilizing hexadecane after adding approx. 1-2 h of 0.05% progesterone with 1% DMF (0.5 g progesterone in 10 ml DMF)
5) 2 ml Probennahme vor (Blindwert), sofort nach Progesterongabe und alle 2-3 h während der Kultivierung Extraktion mit 4 ml5) 2 ml sampling before (blank value), immediately after progesterone administration and every 2-3 hours during cultivation, extraction with 4 ml
Dichlormethan (oder Isobutylmethylketon) und AnalyseDichloromethane (or isobutyl methyl ketone) and analysis
6) Nach ca. 14 h Zugabe von weiteren 3% Hexadecan, Variante B (Abb. 15)6) After approx. 14 h addition of further 3% hexadecane, variant B (Fig. 15)
1 ) 900 ml M (1 % Hexadecan)- Start mit 100 ml 2. Vorkultur Start-ODeoo ca. 1 -1 ,51) 900 ml M (1% hexadecane) - start with 100 ml 2nd preculture start-ODeoo approx. 1 -1.5
2) Nach 14 h Zugabe von 0,05% Progesteron mit 1 % Dichlormethan (0,5 g Progesteron in 10 ml Dichlormethan)2) After 14 h addition of 0.05% progesterone with 1% dichloromethane (0.5 g progesterone in 10 ml dichloromethane)
3) weiter wie Variante A Punkt 5 Analysen: Biomasse (OD6oo) Progesteron-Umsetzung durch 2 ml Probennahme, sofortige Extraktion mit 4 ml Dichlormethan bzw. Isobutylmethylketon Analyse durch TLC, GC oder HPLC3) same as variant A point 5 analyzes: biomass (OD 6 oo) progesterone conversion by 2 ml sampling, immediate extraction with 4 ml dichloromethane or isobutyl methyl ketone analysis by TLC, GC or HPLC
Die Erfindung wird nachfolgend an Hand von in den Abbildungen dargestellten Ausführungsbeispielen noch weiter erläutert. Abb. 1: Nachweis der repetitiven Sequenzen rDNA und ZETA in verschiedenen Y. //po/yf/ca-Stämmen durch Southern-Hybridisierung.The invention is explained in more detail below on the basis of exemplary embodiments illustrated in the figures. Fig. 1: Detection of the repetitive sequences rDNA and ZETA in different Y. // po / yf / ca strains by Southern hybridization.
0,5 μg chromosomale DNA wurden mit dem Restriktionsenzym EcoRI verdaut und gelelektrophoretisch aufgetrennt. Zur Detektion wurden die ZETA-Sequenz (A) aus dem Plasmid p67ICLpro bzw. rDNA (G-Unit)-Sequenz (B) aus dem Plasmid p64ICLpro als Fluorescein-markierte Sonden eingesetzt. Auftragung: 1 λ-DNA EcoRI/H/ndlll, 2 H222, 3 B512-3, 4 B204-12A-213, 5 B204-12C, 6 PO1 d, 7 E150, 8 E1290.5 μg of chromosomal DNA was digested with the restriction enzyme EcoRI and separated by gel electrophoresis. For detection, the ZETA sequence (A) from the plasmid p67ICLpro or rDNA (G-Unit) sequence (B) from the plasmid p64ICLpro were used as fluorescein-labeled probes. Application: 1 λ DNA EcoRI / H / ndlll, 2 H222, 3 B512-3, 4 B204-12A-213, 5 B204-12C, 6 PO1 d, 7 E150, 8 E129
Abb. 2: Restriktionskarten der Ausgangsplasmide für die Konstruktion neuer Vektoren für die multi-copy Integration ins Genom von Y. lipolytica.Fig. 2: Restriction maps of the starting plasmids for the construction of new vectors for multi-copy integration into the genome of Y. lipolytica.
Das Plasmid plNA1067 enthält das im Promotorbereich stark verkürzte URA3d4 Gen als Selektionsmarker für die multi-copy Integration, die Sequenz des ZETA-Elements des LTR (long terminal repeat) aus dem Retrotransposon Ylt1 von Y. lipolytica als Zielort für die Integration und den Promotor und Terminator des XPR2 Gens der alkalische Protease von Y lipolytica. Das Plasmid plNA1064 enthält neben dem URA3d4 Gen und dem Promotor und Terminator des XPR2 Gens ein Fragment aus dem rDNA Gen (G-Einheit) von Y. lipolytica für die Integration ins Genom. Beide Plasmide wurden von Dr. J.-M. Nicaud (INRA-CNRS, Thiveral-Grignon, Frankreich) erhalten.The plasmid plNA1067 contains the URA3d4 gene, which is greatly shortened in the promoter region, as a selection marker for the multi-copy integration, the sequence of the ZETA element of the LTR (long terminal repeat) from the retrotransposon Ylt1 from Y. lipolytica as the destination for the integration and the promoter and Terminator of the XPR2 gene, the alkaline protease from Y lipolytica. In addition to the URA3d4 gene and the promoter and terminator of the XPR2 gene, the plasmid plNA1064 contains a fragment from the rDNA gene (G unit) from Y. lipolytica for integration into the genome. Both plasmids were developed by Dr. J.-M. Nicaud (INRA-CNRS, Thiveral-Grignon, France) received.
Abb. 3: Restriktionskarten der neu konstruierten Basisplasmide pBD67 und pBD64 zur multi-copy Integration in das Genom von Y. lipolytica.Fig. 3: Restriction maps of the newly constructed basic plasmids pBD67 and pBD64 for multi-copy integration into the genome of Y. lipolytica.
Die Plasmide basieren auf dem E coli Vektor pUCBM21. Sie tragen das im Promotor defekte URA3d4 Gen als multi-copy Selektionsmarker. Das Plasmid pBD64 ist für die Integration in die rDNA (G-Unit) geeignet, das Plasmid pBD67 kann zur Integration in das LTR-Element ZETA (long terminal repeat) des Retrotransposons Ylt1 genutzt werden. rDNA = rDNA-Fragment von Y. lipolytica G-Einheit, URA3d4 = defektives URA3 Gen von Y. lipolytica, ampR = Ampicillin Resistenzgen, ZETA = LTR (long terminal repeat) des Retrotransposons Ylt1. Abb. 4: Restriktionskarte der multi-copy „seif cloning" Vektoren p64zblCLpr und p67zb zur Integration von E. co//-freier DNA ins Genom von Yarrowia lipolytica.The plasmids are based on the E coli vector pUCBM21. They carry the URA3d4 gene, which is defective in the promoter, as a multi-copy selection marker. The plasmid pBD64 is suitable for integration into the rDNA (G unit), the plasmid pBD67 can be used for integration into the LTR element ZETA (long terminal repeat) of the retrotransposon Ylt1. rDNA = rDNA fragment from Y. lipolytica G unit, URA3d4 = defective URA3 gene from Y. lipolytica, amp R = ampicillin resistance gene, ZETA = LTR (long terminal repeat) of the retrotransposon Ylt1. Fig. 4: Restriction map of the multi-copy "soap cloning" vectors p64zblCLpr and p67zb for the integration of E. co // - free DNA into the genome of Yarrowia lipolytica.
Vektor basiert auf dem Plasmid pBD67 (Abb 3) und tragt zusätzlich ein verkürztes ZETA-Element Nach Verdau mit der Restπktionsendonuklease Λ/of1 kann die DNA mit Ursprung aus dem Bakteπum E coli abgetrennt werden URA3d4 = Selektionsmarker ZETA = LTR des Retrotransposon Ylt1 aus Yarrowia lipolytica ZETA' = Teil des LTR des Retrotransposons Ylt1 aus Yarrowia lipolytica ampR - Ampicillin-ResistenzgenVector is based on the plasmid pBD67 (Fig. 3) and additionally carries a shortened ZETA element. After digestion with the residual endonuclease Λ / of1, the DNA originating from the bacterium E coli can be separated. URA3d4 = selection marker ZETA = LTR of the retrotransposon Ylt1 from Yarrowia lipolytica ZETA '= part of the LTR of the retrotransposon Ylt1 from Yarrowia lipolytica amp R - ampicillin resistance gene
Abb. 5: Restriktionskarten der multi-copy Vektoren p64ICLpro und p67ICLpro. Das Plasmid p64ICLpro enthalt das rDNA-Fragment und das \JRA3d4 Gen aus plNA1064 und den ICL -/-Promotor Der Sac//-Ort in der rDNA kann zur Linearisierung des Plasmides für eine integrative Transformation in das rDNA-Cluster (G-Einheit) genutzt werden Das Plasmid p67ICLpro enthalt das ZETA Element und das URA3d4 Gen aus dem Plasmid plNA1067 und den /CL 7 -Promotor Der Notl-Ort kann zum Offnen des Plasmides für die anschließende Integration in die ZETA-Elemente des LTR (long terminal repeat des Retrotransposons Ylt1 ) des Wirtsgenoms genutzt werden Heterologe Gene (lacZ oder CYP17) können nach Fusion mit dem ICL1- Terminator leicht in diese Plasmide eingefugt werden Dadurch werden komplette Expressionskassetten in den abgeleiteten Plasmiden geschaffen (vgl Abb 5 und Abb 6, Erläuterungen der Abkürzungen vgl auch Abb 3)Fig. 5: Restriction maps of the multi-copy vectors p64ICLpro and p67ICLpro. The plasmid p64ICLpro contains the rDNA fragment and the \ JRA3d4 gene from plNA1064 and the ICL - / - promoter. The Sac // site in the rDNA can be used to linearize the plasmid for an integrative transformation into the rDNA cluster (G unit). The plasmid p67ICLpro contains the ZETA element and the URA3d4 gene from the plasmid plNA1067 and the / CL 7 promoter. The NotI site can be used to open the plasmid for subsequent integration into the ZETA elements of the LTR (long terminal repeat of the retrotransposon Ylt1) of the host genome. Heterologous genes (lacZ or CYP17) can easily be inserted into these plasmids after fusion with the ICL1 terminator. This creates complete expression cassettes in the derived plasmids (see Fig. 5 and Fig. 6, explanations of the abbreviations see also Fig 3)
Abb. 6: Restriktionskarten der multi-copy Vektoren p64IL43 und p67IL43 zur heterologen Expression des lacZ Gens aus E. coli in der Hefe Y. lipolytica.Fig. 6: Restriction maps of the multi-copy vectors p64IL43 and p67IL43 for the heterologous expression of the lacZ gene from E. coli in the yeast Y. lipolytica.
Die Vektoren basieren auf den Plasmiden pBD64 und pBD67 (vgl Abb 3) und tragen die Expressionskassette für das lacZ Gen unter der Kontrolle des ICL1 -Promotors und Terminators rDNA = rDNA-Fragment von Y lipolytica G-Einheit, URA3d4 = defektives URA3 Gen, ampR = Ampicillin Resistenzgen, ICLpro = /C ^-Promotor, ICLI = ICL1-\ntron, ICLt = /C/_ 7" -Terminator, ZETA = LTR ZETA (long terminal repeat) des Retrotransposons Ylt1 von Y lipolytica Abb. 7: Restriktionskarten der multi-copy Expressionsvektoren Plasmid p64IC17α und p67IC17α für die heterologe Expression des Cytochrom P45017α (CYP17) der Nebenniere des Rindes in Yarrowia lipolytica.The vectors are based on the plasmids pBD64 and pBD67 (see FIG. 3) and carry the expression cassette for the lacZ gene under the control of the ICL1 promoter and terminator. RDNA = rDNA fragment from Y lipolytica G unit, URA3d4 = defective URA3 gene, amp R = ampicillin resistance gene, ICLpro = / C ^ promoter, ICLI = ICL1- \ ntron, ICLt = / C / _ 7 " terminator, ZETA = LTR ZETA (long terminal repeat) of the retrotransposon Ylt1 from Y lipolytica Fig. 7: Restriction maps of the multi-copy expression vectors plasmid p64IC17α and p67IC17α for the heterologous expression of the cytochrome P45017α (CYP17) of the adrenal gland in Yarrowia lipolytica.
Die Vektoren basieren auf den Plasmiden pBD64 und pBD67 (vgl. Abb. 3) und tragen die Expressionskassette für CYP17 P450 Gen unter der Kontrolle des ICL1 -Promotors und Terminators. Erläuterungen der Abkürzungen vgl. Abb. 6.The vectors are based on the plasmids pBD64 and pBD67 (see FIG. 3) and carry the expression cassette for the CYP17 P450 gene under the control of the ICL1 promoter and terminator. Explanations of the abbreviations see Fig. 6.
Abb. 8: Transformationseffizienz von kompetenten Zellen der Stämme PO1d und E129 Zellen wurden mit 200 ng linearisierter Plasmid-DNA und 5,0 μg Carrier-DNA transformiert. Die Transformanden wurden nach 3-14 Tagen beobachtet.Fig. 8: Transformation efficiency of competent cells from the strains PO1d and E129 cells were transformed with 200 ng linearized plasmid DNA and 5.0 μg carrier DNA. The transformants were observed after 3-14 days.
Abb. 9: Restriktionskarten der autonom replizierenden Plasmide YEp5117α und plC17α zur heterologen Expression des Cytochrom P45017α der Nebenniere des Rindes in der Hefe Yarrowia lipolytica und in der Hefe Saccharomyces cerevisiae.Fig. 9: Restriction maps of the autonomously replicating plasmids YEp5117α and plC17α for the heterologous expression of the cytochrome P45017α of the adrenal gland of the bovine in the yeast Yarrowia lipolytica and in the yeast Saccharomyces cerevisiae.
Der Vektor YEp5117α wurde durch Dr. W.-H. Schunck (MDC Berlin-Buch) zur Verfügung gestellt. Für die Herstellung des Vektors YEp5117α wurde die cDNA für das CYP17 aus dem Plasmid pCMV17α in mehreren Schritten in den high-copy Hefe- Shuttle-Vektor YEp51 (LEU2, 2 μ ARS, Kopiezahlen von 50-100) kloniert. Der Vektor YEp5117α erlaubt die durch Galactose induzierbare Expression des P45017α in der Hefe S. cerevisiae unter Kontrolle des GAL10-Promotors. Die cDNA für das CYP17 wurde aus dem Plasmid pCMV17α (J Biol Chem 266:5898-5904, 1991 ) gewonnen und kodiert für das Cytochrom P45017α der Nebenniere des Rindes. Dieses Plasmid wurde freundlicherweise von Prof. M. Waterman (Vanderbilt Universität Nashville) zur Verfügung gestellt. Das Plasmid plC17α basiert auf dem autonom replizierenden Iow- copy Vektor plNA237 (ARS18/CEN, gewährleistet 1-3 Kopien pro Zelle) für Y. lipolytica und enthält eine Expressionskassette für das Cytochrom P45017α (CYP17) unter der Kontrolle des ICL1 -Promotors (ICLp/ICLi/CYP77/ICLt). Die cDNA CYP17, codierend für das Cytochrom P45017α des Rindes, wurde in mehreren Schritten in den Iow-copy Vektor pYLI131 D für Y. lipolytica anstelle des ICL1 Strukturgens eingesetzt. Dazu wurde die cDNA mit Hilfe der rekombinanten PCR direkt am T36oG36i des 3'-Endes des Introns im ICL -/-Promotor fusioniert. Das resultierende Plasmid plC17α erlaubt die Expression des P45017α unter Kontrolle des regulierten ICL1 -Promotors nach korrektem Spleißen des Introns und der Neuformierung des TranslationsstartsThe vector YEp5117α was developed by Dr. W.-H. Schunck (MDC Berlin-Buch) provided. For the production of the vector YEp5117α, the cDNA for the CYP17 from the plasmid pCMV17α was cloned in several steps into the high-copy yeast shuttle vector YEp51 (LEU2, 2 μ ARS, copy numbers from 50-100). The vector YEp5117α allows galactose-inducible expression of P45017α in the yeast S. cerevisiae under the control of the GAL10 promoter. The cDNA for the CYP17 was obtained from the plasmid pCMV17α (J Biol Chem 266: 5898-5904, 1991) and codes for the cytochrome P45017α of the bovine adrenal gland. This plasmid was kindly provided by Prof. M. Waterman (Vanderbilt University Nashville). The plasmid plC17α is based on the autonomously replicating Iow copy vector plNA237 (ARS18 / CEN, ensures 1-3 copies per cell) for Y. lipolytica and contains an expression cassette for the cytochrome P45017α (CYP17) under the control of the ICL1 promoter (ICLp / ICLi / CYP77 / ICLt). The cDNA CYP17, coding for the cytochrome P45017α of the bovine, was used in several steps in the Iow-copy vector pYLI131 D for Y. lipolytica instead of the ICL1 structural gene. For this purpose, the cDNA was recombinant PCR directly at the T 3 6oG 3 6i of the 3 'end of the Introns fused in the ICL - / - promoter. The resulting plasmid plC17α allows expression of the P45017α under the control of the regulated ICL1 promoter after correct splicing of the intron and reforming of the translation start
Abb. 10: Kopiezahlen der Expressionskassetten für das lacZ Gen unter Kontrolle des ICL1 -Promotors in integrativen multi-copy Transformanden des Y. lipolytica Stammes PO1d mit dem Plasmid p64IL43.Fig. 10: Copy numbers of the expression cassettes for the lacZ gene under the control of the ICL1 promoter in integrative multi-copy transformants of the Y. lipolytica strain PO1d with the plasmid p64IL43.
Ausgewählte Transformanden mit dem integrativen Plasmid p64IL43 (vgl. Abb. 6) wurden in YNB/Glucose Medium kultiviert. Die Kopiezahl wurde durch Southern Blot Hybridisierung mit dem 32P-markierten ICL 7-lntron als Sonde bestimmt. Die Kopiezahl wurde aus dem Verhältnis der Bandenintensität bei 3.8 kb (lacZ Kassette) und 2.2 kb (ICL1 als eine Kopie pro Genom) kalkuliert. Als Vergleich diente eine Transformande mit dem autonom replizierenden ARS/CEN Plasmid plL43.Selected transformants with the integrative plasmid p64IL43 (see Fig. 6) were cultivated in YNB / glucose medium. The copy number was determined by Southern blot hybridization with the 32 P-labeled ICL 7 intron as a probe. The copy number was calculated from the ratio of the band intensity at 3.8 kb (lacZ cassette) and 2.2 kb (ICL1 as one copy per genome). A transformant with the autonomously replicating ARS / CEN plasmid plL43 served as a comparison.
Abb. 11 : Abhängigkeit der maximalen spezifischen ß-Galactosidase-Aktivität von der Kopiezahl der Expressionskassetten in Transformanden von Yarrowia lipolytica PO1d, die durch das Iow-copy replikative Plasmid plL43 oder durch das multi-copy integrative Plasmid p64IL43 transformiert wurden. Dargestellt ist ein Vergleich der maximalen spezifischen ß-Galactosidase-Aktivitäten nach 10 bis 12 h Kultivierung im Minimalmedium mit 1 % Ethanol als induzierender C- Quelle. Die ß-Galactosidase-Aktivität wurde als Miller Units bestimmt. Die Kopiezahl der Expressionskassette wurde in jeder Transformande mit Zellen der Glucose- Vorkultur bestimmt (vgl. Abb. 10).Fig. 11: Dependence of the maximum specific ß-galactosidase activity on the copy number of the expression cassettes in transformants from Yarrowia lipolytica PO1d, which were transformed by the Iow-copy replicative plasmid plL43 or by the multi-copy integrative plasmid p64IL43. A comparison of the maximum specific ß-galactosidase activities after 10 to 12 h of cultivation in minimal medium with 1% ethanol as an inducing C source is shown. The β-galactosidase activity was determined as Miller units. The copy number of the expression cassette was determined in each transformant with cells from the glucose preculture (cf. FIG. 10).
Abb. 12: Nachweis der funktionellen Expression von Cytochrom P45017α der Nebenniere des Rindes in einer Transformande der Hefe Yarrowia lipolytica mit dem Iow-copy ARS/CEN Plasmid plC17α unter Kontrolle des ICL "/-Promoters.Fig. 12: Evidence of the functional expression of cytochrome P45017α of the adrenal gland in a transformant of the yeast Yarrowia lipolytica with the Iow-copy ARS / CEN plasmid plC17α under the control of the ICL "/ promoter.
(A) Dünnschichtchromatographische Analyse der Umsetzung von 3H-markiertem Progesteron (P, 100 nmol in 1 ml Versuchsansatz) durch intakte Zellen (1 x 108 (A) Thin-layer chromatographic analysis of the conversion of 3 H-labeled progesterone (P, 100 nmol in 1 ml test batch) by intact cells (1 x 10 8
Zellen/ml) bei der Inkubation von auf Hexadecan kultivierten Transformanden des Stammes Y. lipolytica B204-12A-213 mit dem Plasmid plC17α und plNA237 (als Negativkontrolle). Der Reaktionsansatz wurde mit 2 ml Dichlormethan extrahiert, bis zur Trockne eingedampft, in jeweils 100 μl Laufmittel (Chloroform/ Essigsäureethylester 3:1 ) gelöst und dünnschichtchromatographisch aufgetrennt. Die Verteilung der Radioaktivität wurde mit einem Bertholdt-Radioscanner bestimmt. Die Laufstrecke für das Hauptprodukt war identisch mit dem des 17α-Hydroxy- Progesterons (17αHP).Cells / ml) during the incubation of transformants of the cultured on hexadecane Strain Y. lipolytica B204-12A-213 with the plasmid plC17α and plNA237 (as a negative control). The reaction mixture was extracted with 2 ml of dichloromethane, evaporated to dryness, dissolved in 100 μl of eluent (chloroform / ethyl acetate 3: 1) and separated by thin layer chromatography. The distribution of radioactivity was determined using a Bertholdt radio scanner. The running distance for the main product was identical to that of the 17α-hydroxy progesterone (17αHP).
(B) Cytochrom P45017α katalysierte Umwandlung von Progesteron (P) in das Produkt 17α-Hydroxy-Progesteron (17αHP).(B) Cytochrome P45017α catalyzed conversion of progesterone (P) into the product 17α-hydroxy-progesterone (17αHP).
Abb. 13: Vergleich der Expressionssysteme für Cytochrom P45017α in den Hefen Yarrowia lipolytica (Iow-copy Plasmid plC17α und Saccharomyces cerevisiae (multi-copy Plasmid YEp5117α) bei der Nutzung von autonom replizierenden Plasmiden.Fig. 13: Comparison of the expression systems for cytochrome P45017α in the yeast Yarrowia lipolytica (Iow-copy plasmid plC17α and Saccharomyces cerevisiae (multi-copy plasmid YEp5117α) when using autonomously replicating plasmids.
Abb. 14: Vergleich des spezifischen Gehaltes von Cytochrom P45017α nach heterologer Expression in den Hefen Yarrowia lipolytica und Saccharomyces cerevisiae von Plasmiden mit hoher Kopiezahl.Fig. 14: Comparison of the specific content of cytochrome P45017α after heterologous expression in the yeasts Yarrowia lipolytica and Saccharomyces cerevisiae of plasmids with a high copy number.
Maximalwerte des spektral mit Hilfe des CO-Differenzspektrums bestimmbaren P450 Gehaltes in der multi-copy Transformande T4 von Y. lipolytica PO1 d (Integration von 8-10 Kopien der Expressionskassette mit Hilfe des Plasmides p67IC17α Expression unter Kontrolle des ICL ^-Promoters) bei Kultivierung auf 1 % Ethanol im Minimalmedium. Als Vergleich sind Werte aufgeführt, die mit dem autonom replizierenden high-copy Plasmid YEp5117 (ca. 50 Kopien pro Zelle) im Stamm S. cerevisiae GRF18 bei Kultivierung auf Galactose (Expression unter Kontrolle des GAL /0-Promotors) erzielt wurden.Maximum values of the spectrally determinable P450 content in the multi-copy transformande T4 of Y. lipolytica PO1 d (integration of 8-10 copies of the expression cassette using the plasmid p67IC17α expression under control of the ICL ^ promoter) during cultivation on 1% ethanol in the minimal medium. For comparison, values are listed which were achieved with the autonomously replicating high-copy plasmid YEp5117 (approx. 50 copies per cell) in the S. cerevisiae GRF18 strain when cultivated for galactose (expression under the control of the GAL / 0 promoter).
Abb. 15: Kultivierung des diploiden Yarrowia lipolytica Stammes A15T4 auf Hexadecan (C16) und Biotransformation von Progesteron in 17α-Hydroxy- Progesteron. Vorkultur auf 1 % Glucose, Kultur in 1 L Bioreaktor auf 1 % C16. Nach 14 h Kultivierung Zugabe von 0.5 g Progesteron in 10 ml Dimethylformamid (DMF) und Zugabe von 2 % C16. Fig. 15: Cultivation of the diploid Yarrowia lipolytica strain A15T4 on hexadecane (C16) and biotransformation of progesterone in 17α-hydroxy-progesterone. Pre-culture on 1% glucose, culture in 1 L bioreactor on 1% C16. After 14 h of cultivation, add 0.5 g of progesterone in 10 ml of dimethylformamide (DMF) and add 2% of C16.

Claims

Patentansprüche claims
1. Rekombinante haploide oder diploide Yarrowia (Y.) lipolytica Zellen, dadurch gekennzeichnet, daß die Zellen Plasmide mit Expressionskassetten beinhalten, wobei die Expressionskassetten aus in Y lipolytica funktioneil aktiven1. Recombinant haploid or diploid Yarrowia (Y.) lipolytica cells, characterized in that the cells contain plasmids with expression cassettes, the expression cassettes being active in Y lipolytica
Promotoren und Terminatoren und Genen oder cDNA zur Expression von Oligopeptiden oder Proteinen bestehen und damit Eigenschaften ausbilden, die zur Stoffumwandlung ausgenutzt werden.Promoters and terminators and genes or cDNA exist for the expression of oligopeptides or proteins and thus develop properties which are used for the conversion of substances.
2. Zellen nach Anspruch 1 , dadurch gekennzeichnet, daß die Zellen Expressionskassetten zur Expression von Genen oder cDNA, codierend für2. Cells according to claim 1, characterized in that the cells expression cassettes for the expression of genes or cDNA, coding for
Cytochrom P450 Enzyme, enthalten.Cytochrome P450 enzymes.
3. Zellen nach Anspruch 1 , dadurch gekennzeichnet, daß die Zellen Expressionskassetten zur Expression von Genen oder cDNA, codierend für Elektronentransfersysteme zur Übertragung von Elektronen auf Cytochrom P450 Enzyme (z.B. NADPH-abhängige Cytochrom P450 Reduktase, Cytochrom B5,3. Cells according to claim 1, characterized in that the cells expression cassettes for the expression of genes or cDNA, coding for electron transfer systems for the transfer of electrons to cytochrome P450 enzymes (eg NADPH-dependent cytochrome P450 reductase, cytochrome B 5 ,
Adrenodoxin und/oder Adrenodoxin-Reduktase), enthalten.Adrenodoxin and / or adrenodoxin reductase).
4. Zellen nach einem der Ansprüche 1 bis 3, dadurch gekennzeichnet, daß die Zellen verschiedene Expressionskassetten zur gleichzeitigen Expression (Koexpression) von Genen, codierend für Elektronentransfersysteme zur Übertragung von Elektronen auf Cytochrom P450 Enzyme und Cytochrom P4504. Cells according to one of claims 1 to 3, characterized in that the cells different expression cassettes for the simultaneous expression (co-expression) of genes, coding for electron transfer systems for the transfer of electrons to cytochrome P450 enzymes and cytochrome P450
Proteine, enthalten.Proteins.
5. Zellen nach einem der Ansprüche 1 bis 4, dadurch gekennzeichnet, daß die Zellen Expressionskassetten enthalten, bestehend aus dem Promotor und Terminator der homologen Isocitratlyase (ICL1 Gen) und Genen zur heterologen Expression.5. Cells according to one of claims 1 to 4, characterized in that the cells contain expression cassettes consisting of the promoter and terminator of the homologous isocitrate lyase (ICL1 gene) and genes for heterologous expression.
6. Zellen nach Anspruch 2 oder 4, dadurch gekennzeichnet, daß die Zellen Verbindungen, die native oder artifizielle Cytochrom P450 Enzymsubstrate sind, aufnehmen, enzymatisch umwandeln, in der Zelle akkumulieren oder an die Umgebung abgeben. 6. Cells according to claim 2 or 4, characterized in that the cells take up compounds which are native or artificial cytochrome P450 enzyme substrates, convert them enzymatically, accumulate in the cell or release them to the environment.
7. Zellen nach Anspruch 6, dadurch gekennzeichnet, daß die Zellen Steroide oder Analoga aufnehmen, enzymatisch umwandeln und in der Zelle akkumulieren oder an die Umgebung abgeben. 7. Cells according to claim 6, characterized in that the cells take up steroids or analogs, convert them enzymatically and accumulate in the cell or release them to the environment.
8. Zellen nach Anspruch 6 oder 7, dadurch gekennzeichnet, daß die Zellen diese Eigenschaften unter physiologischen Bedingungen z.B. bei der Verwertung von Glucose, Glycerol, Ethanol, Fettsäuren oder Alkanen ausbilden.8. Cells according to claim 6 or 7, characterized in that the cells have these properties under physiological conditions e.g. train in the use of glucose, glycerol, ethanol, fatty acids or alkanes.
9. Zellen nach Anspruch 8, dadurch gekennzeichnet, daß die Zellen diese Eigenschaften unter physiologischen Bedingungen besonders bei der9. Cells according to claim 8, characterized in that the cells have these properties under physiological conditions especially in the
Verwertung von mittel- und langkettigen n-Alkanen ausbilden.Form recovery of medium and long chain n-alkanes.
10. Zellen nach einem der Ansprüche 1 bis 9, dadurch gekennzeichnet, daß die Zellen integrative multi-copy Plasmide, bestehend aus E co//'-freier DNA („seif cloning vectors"), einem Selektionsmarkergen zur Selektion von multi-copy Transformanden und aus anderen chromosomalen Y. lipolytica DNA-Fragmenten, die geeignet sind zur Integration ins Genom der Hefe Y. lipolytica, enthalten.10. Cells according to one of claims 1 to 9, characterized in that the cells are integrative multi-copy plasmids consisting of E co // ' -free DNA ("seif cloning vectors"), a selection marker gene for the selection of multi-copy transformants and from other chromosomal Y. lipolytica DNA fragments which are suitable for integration into the genome of the yeast Y. lipolytica.
11. Zellen nach einem der Ansprüche 1 bis 9, dadurch gekennzeichnet, daß die Zellen integrative multi-copy Plasmide, bestehend aus Replikons bakteriellen Ursprungs, einem Selektionsmarkergen zur Selektion von multi-copy Transformanden und aus anderen chromosomalen Y. lipolytica DNA-Fragmenten, die geeignet sind zur Integration ins Genom der Hefe Y. lipolytica, enthalten.11. Cells according to one of claims 1 to 9, characterized in that the cells are integrative multi-copy plasmids consisting of replicons of bacterial origin, a selection marker gene for the selection of multi-copy transformants and other chromosomal Y. lipolytica DNA fragments which are suitable for integration into the genome of the yeast Y. lipolytica.
12. Plasmide zur Erzeugung rekombinanter haploider oder diploider Yarrowia (Y.) lipolytica Zellen nach einem der Ansprüche 1 bis 11 , dadurch gekennzeichnet, daß die Plasmide Expressionskassetten, bestehend aus einem in Y. lipolytica funktionell aktiven Promotor und Terminator und einem Gen oder einer cDNA zur Expression von Oligopeptiden und Proteinen, in der Multiple cloning site enthalten.12. Plasmids for generating recombinant haploid or diploid Yarrowia (Y.) lipolytica cells according to one of claims 1 to 11, characterized in that the plasmids expression cassettes, consisting of a promoter and terminator functionally active in Y. lipolytica and a gene or a cDNA for the expression of oligopeptides and proteins, contained in the multiple cloning site.
13. Plasmide nach Anspruch 12, dadurch gekennzeichnet, daß die Plasmide Expressionskassetten, bestehend aus dem Y. lipolytica ICL1 -Promotor und ICL1- Terminator und einem Gen zur Expression von Oligopeptiden und Proteinen, in die Multiple cloning site enthalten.13. Plasmids according to claim 12, characterized in that the plasmids contain expression cassettes, consisting of the Y. lipolytica ICL1 promoter and ICL1 terminator and a gene for the expression of oligopeptides and proteins, in the multiple cloning site.
14. Plasmide nach Anspruch 12 oder 13, dadurch gekennzeichnet, daß die Plasmide vielfach ins Genom der Hefe Y. lipolytica integriert sind.14. Plasmids according to claim 12 or 13, characterized in that the plasmids are often integrated into the genome of the yeast Y. lipolytica.
15. Plasmide nach einem der Ansprüche 12 bis 14, dadurch gekennzeichnet, daß die Plasmide in die Sequenzen des LTR-ZETA-Element ("Long Terminal Repeat" des15. Plasmid according to one of claims 12 to 14, characterized in that the plasmids in the sequences of the LTR-ZETA element ("Long Terminal Repeat" of
Retrotransposons Ylt1 ) von Y. lipolytica integriert sind.Retrotransposons Ylt1) from Y. lipolytica are integrated.
16. Plasmide nach einem der Ansprüche 12 bis 14, dadurch gekennzeichnet, daß die Plasmide in die Sequenzen der rDNA integriert sind. 16. Plasmids according to one of claims 12 to 14, characterized in that the plasmids are integrated into the sequences of the rDNA.
17. Plasmide nach Anspruch 16, dadurch gekennzeichnet, daß die Plasmide in die Sequenzen der G-Einheit der rDNA integriert sind.17. Plasmids according to claim 16, characterized in that the plasmids are integrated into the sequences of the G unit of the rDNA.
18. Plasmide nach Anspruch 14, dadurch gekennzeichnet, daß die Plasmide illegitim ins Genom integriert sind. 18. Plasmids according to claim 14, characterized in that the plasmids are illegitimately integrated into the genome.
19. Plasmide nach einem der Ansprüche 12 bis 18, dadurch gekennzeichnet, daß die Plasmide zur Expression von heterologen Proteinen in transformierten Hefezellen geeignet sind.19. Plasmids according to one of claims 12 to 18, characterized in that the plasmids are suitable for the expression of heterologous proteins in transformed yeast cells.
20. Verfahren zur Herstellung von rekombinanten haploiden oder diploiden Yarrowia (Y.) lipolytica Zellen nach einem der Ansprüche 1 bis 19, dadurch gekennzeichnet, daß die Expressionskassetten in die Multiple cloning site der20. A method for producing recombinant haploid or diploid Yarrowia (Y.) lipolytica cells according to one of claims 1 to 19, characterized in that the expression cassettes in the multiple cloning site of
Plasmide eingesetzt werden und die Y. lipolytica Zellen mit den die Expressionskassetten tragenden Plasmiden transformiert werden.Plasmids are used and the Y. lipolytica cells are transformed with the plasmids carrying the expression cassettes.
21. Verfahren nach Anspruch 20, dadurch gekennzeichnet, daß die Plasmide auf Replikons bakteriellen Ursprungs aufgebaut werden. 21. The method according to claim 20, characterized in that the plasmids are built on replicons of bacterial origin.
22. Verfahren nach Anspruch 20 oder 21 , dadurch gekennzeichnet, daß die Plasmide aus zwei ZETA-Elemente ("Long Terminal Repeats" LTR des Retrotransposons Yltl aus Y. lipolytica erzeugt werden, die den DNA-Anteil aus E coli flankieren und vor der Transformation der Y. lipolytica Zellen der E coli DNA-Anteil abgetrennt wird. 22. The method according to claim 20 or 21, characterized in that the plasmids are generated from two ZETA elements ("Long Terminal Repeats" LTR of the retrotransposon Yltl from Y. lipolytica, which flank the DNA portion from E coli and before the transformation the Y. lipolytica cells the E coli DNA portion is separated.
23. Verfahren nach Anspruch 20 oder 21 , dadurch gekennzeichnet, daß die Plasmide aus zwei rDNA-Elemente aus Y. lipolytica erzeugt werden, die den DNA-Anteil aus E. coli flankieren und vor der Transformation der Y. lipolytica Zellen der E. coli DNA-Anteil abgetrennt wird.23. The method according to claim 20 or 21, characterized in that the plasmids are generated from two rDNA elements from Y. lipolytica, which flank the DNA portion from E. coli and before the transformation of the Y. lipolytica cells of E. coli DNA portion is separated.
24. Verwendung von rekombinanter haploider oder diploiden Y. lipolytica Zellen nach einem der Ansprüche 1 bis 19, dadurch gekennzeichnet, daß die transformierten24. Use of recombinant haploid or diploid Y. lipolytica cells according to one of claims 1 to 19, characterized in that the transformed
Zellen heterologe Proteine synthetisieren.Cells synthesize heterologous proteins.
25. Verwendung nach Anspruch 24, dadurch gekennzeichnet, daß nachdem von den transformierten Zellen heterologe Proteine synthetisieren worden sind, die transformierten Zellen zur gezielten Stoffumwandlung eingesetzt werden.25. Use according to claim 24, characterized in that after heterologous proteins have been synthesized by the transformed cells, the transformed cells are used for targeted substance conversion.
Hierzu 15 Blatt Zeichnungen 15 drawings
PCT/DE1999/002174 1998-07-10 1999-07-09 Recombinant haploid or diploid yarrowia lipolytica cells for the functional heterologous expression of cytochrome p450 systems WO2000003008A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19830905.8 1998-07-10
DE19830905 1998-07-10

Publications (2)

Publication Number Publication Date
WO2000003008A2 true WO2000003008A2 (en) 2000-01-20
WO2000003008A3 WO2000003008A3 (en) 2000-04-27

Family

ID=7873597

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE1999/002174 WO2000003008A2 (en) 1998-07-10 1999-07-09 Recombinant haploid or diploid yarrowia lipolytica cells for the functional heterologous expression of cytochrome p450 systems

Country Status (2)

Country Link
DE (1) DE19932811A1 (en)
WO (1) WO2000003008A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6351745B1 (en) 1996-02-28 2002-02-26 Netzero, Inc. Communication system for distributing such message as advertisement to user of terminal equipment
US6639608B1 (en) 1996-01-23 2003-10-28 Yuichiro Itakura System for displaying two independent images received from network
WO2004009828A1 (en) * 2002-07-16 2004-01-29 Technische Universität Dresden Method for the biotechnological production of citric acid by means of a genetically-modified yeast yarrowia lipolytica
US6711551B1 (en) 1996-06-05 2004-03-23 Netzero, Inc. Information provider, terminal and system and recording medium for the terminal
CN114807182A (en) * 2022-06-07 2022-07-29 天津大学 Yeast strain for degrading long-chain alkane and application thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19963690A1 (en) * 1999-11-23 2001-06-13 Rhein Biotech Proz & Prod Gmbh Vectors and methods for producing recombinant proteins in fungi

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19507546A1 (en) * 1995-03-03 1996-09-12 Max Delbrueck Centrum Process for the hydroxylation of long chain alkanes, fatty acids and other alkyl compounds
DE19525282A1 (en) * 1995-06-29 1997-01-02 Max Delbrueck Centrum Yarrowia lipolytica expression cassette contg. ICL1 promoter and terminator

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19507546A1 (en) * 1995-03-03 1996-09-12 Max Delbrueck Centrum Process for the hydroxylation of long chain alkanes, fatty acids and other alkyl compounds
DE19525282A1 (en) * 1995-06-29 1997-01-02 Max Delbrueck Centrum Yarrowia lipolytica expression cassette contg. ICL1 promoter and terminator

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DALL LE M -T ET AL: "MULTIPLE-COPY INTEGRATION IN THE YEAST YARROWIA LIPOLYTICA" CURRENT GENETICS,US,NEW YORK, NY, Bd. 26, Nr. 1, 1. Januar 1994 (1994-01-01), Seiten 38-44, XP002040754 ISSN: 0172-8083 in der Anmeldung erw{hnt *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6639608B1 (en) 1996-01-23 2003-10-28 Yuichiro Itakura System for displaying two independent images received from network
US6351745B1 (en) 1996-02-28 2002-02-26 Netzero, Inc. Communication system for distributing such message as advertisement to user of terminal equipment
US6711551B1 (en) 1996-06-05 2004-03-23 Netzero, Inc. Information provider, terminal and system and recording medium for the terminal
WO2004009828A1 (en) * 2002-07-16 2004-01-29 Technische Universität Dresden Method for the biotechnological production of citric acid by means of a genetically-modified yeast yarrowia lipolytica
CN114807182A (en) * 2022-06-07 2022-07-29 天津大学 Yeast strain for degrading long-chain alkane and application thereof
CN114807182B (en) * 2022-06-07 2023-07-25 天津大学 Yeast strain for degrading long-chain alkane and application thereof

Also Published As

Publication number Publication date
DE19932811A1 (en) 2000-01-20
WO2000003008A3 (en) 2000-04-27

Similar Documents

Publication Publication Date Title
Larroudé et al. Synthetic biology tools for engineering Yarrowia lipolytica
Hadfield et al. An efficient chloramphenicol-resistance marker for Saccharomyces cerevisiae and Escherichia coli
DD255544A5 (en) Method for the site-selective gene modification of yeasts of the genus Pichia
KR20140033002A (en) A yeast cell for the production of terpenes and uses thereof
EP2410047B9 (en) Oxidoreductase and its use for the reduction of secodione derivatives
WO2000003008A2 (en) Recombinant haploid or diploid yarrowia lipolytica cells for the functional heterologous expression of cytochrome p450 systems
Dumas et al. Hydrocortisone made in yeast: Metabolic engineering turns a unicellular microorganism into a drug‐synthesizing factory
DE69635525T2 (en) GENERALLY MANUFACTURED HEFESTÄMME
DE19507546C2 (en) Process for the regioselective hydroxylation of long-chain alkanes, fatty acids and other alkyl compounds
EP2791332A1 (en) Fungal strains with genetic modification relating to a carboxylic acid transporter
CA2293737A1 (en) Transformed yeast strains and their use for the production of monoterminal and diterminal aliphatic carboxylates
Madzak Yarrowia lipolytica engineering as a source of microbial cell factories
EP0300168B1 (en) Process for the glutathione synthesis in yeast
DE69918752T2 (en) HEFESTAMMS WITH BROKEN ATF2 GENES AND THEIR USES
US10400261B2 (en) Genetically transformed yeasts capable of producing a molecule of interest at a high titre
KR102207288B1 (en) Expression vectors for optimal expression of mutated Upc2p and method for overproducing sterol precursors using the same
JP7157237B2 (en) Recombinant yeast strain having sterol-producing ability, production method and use thereof
EP1918379A1 (en) Expression vectors for multiple gene integration and Overexpression of homologous and heterologous proteins in yeasts of the species Arxula
EP1472355A1 (en) Method for the production of zymosterol and/or the biosynthetic intermediate and/or subsequent products thereof in transgenic organisms
KR102185428B1 (en) Expression vectors for optimal expression of mutated Upc2p and method for overproducing sterol precursors using the same
US20230183722A1 (en) Gene expression system for rapid construction of multiple-gene pathway in oleaginous yeasts
WO2004083407A1 (en) Method for producing ergosta-5,7-dienol and/or biosynthetic intermediate and/or secondary products thereof in transgenic organisms
Cregg The Pichia System
WO2014191205A1 (en) Yeast strain and method for producing lycopene
EP3530739A1 (en) Expression system for productin of a heterologous protein, plasmid expression vectors, method of construction of a recombinant strain of psychrotolerant yeast debaryomyces macquariensis and method of protein production by the recombinant yeast strain

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): PL RU UA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): PL RU UA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 1999960682

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999960682

Country of ref document: EP

122 Ep: pct application non-entry in european phase